<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005055.pub3" GROUP_ID="ANAESTH" ID="299703100121224889" MERGED_FROM="" MODIFIED="2014-07-03 13:14:23 +0100" MODIFIED_BY="Jane Cracknell" REVIEW_NO="095" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2014-07-03 13:14:23 +0100" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2014-07-02 17:25:30 +0100" MODIFIED_BY="Jane Cracknell">Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease</TITLE>
<CONTACT MODIFIED="2014-07-03 13:14:23 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="17856" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Matthew</FIRST_NAME><LAST_NAME>Bizzarro</LAST_NAME><POSITION>Associate Professor in Pediatrics</POSITION><EMAIL_1>matthew.bizzarro@yale.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Yale University School of Medicine</ORGANISATION><ADDRESS_1>333 Cedar Street WP493</ADDRESS_1><ADDRESS_2>P.O. Box 208064</ADDRESS_2><CITY>New Haven</CITY><ZIP>06520-8064</ZIP><REGION>CT</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 203-688-2320</PHONE_1><FAX_1>+ 203-688-5426</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-07-03 13:14:23 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="17856" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Matthew</FIRST_NAME><LAST_NAME>Bizzarro</LAST_NAME><POSITION>Associate Professor in Pediatrics</POSITION><EMAIL_1>matthew.bizzarro@yale.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Yale University School of Medicine</ORGANISATION><ADDRESS_1>333 Cedar Street WP493</ADDRESS_1><ADDRESS_2>P.O. Box 208064</ADDRESS_2><CITY>New Haven</CITY><ZIP>06520-8064</ZIP><REGION>CT</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 203-688-2320</PHONE_1><FAX_1>+ 203-688-5426</FAX_1></ADDRESS></PERSON><PERSON ID="19277" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ian</FIRST_NAME><LAST_NAME>Gross</LAST_NAME><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>ian.gross@yale.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Yale University School of Medicine</ORGANISATION><ADDRESS_1>333 Cedar Street</ADDRESS_1><CITY>New Haven</CITY><ZIP>06520-8064</ZIP><REGION>CT</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+001 20 3688 2320</PHONE_1><FAX_1>+001 20 3688 5426</FAX_1></ADDRESS></PERSON><PERSON ID="E4FF562582E26AA2009C393D20B81333" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Fabiano</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Barbosa</LAST_NAME><POSITION>Anesthesiologist</POSITION><EMAIL_1>fabianotimbo@yahoo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Medicine</DEPARTMENT><ORGANISATION>Hospital Geral do Estado Professor Osvaldo Brandão Vilela</ORGANISATION><ADDRESS_1>Siqueira Campos Avenue, 2095</ADDRESS_1><ADDRESS_2>Trapiche da Barra</ADDRESS_2><CITY>Maceió</CITY><ZIP>57010000</ZIP><REGION>Alagoas</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-02-18 14:56:14 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="12" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="12" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-03 13:05:37 +0100" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-03 13:05:34 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="3" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>The search was originally run in 2004 (<LINK REF="REF-Bizzarro-2005" TYPE="REFERENCE">Bizzarro 2005</LINK>). In this updated review we reran the search strategy until December 2013.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-07-03 13:05:37 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="3" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>We found three new studies. After we assessed the full articles for eligibility criteria we excluded these articles in (<LINK REF="STD-Checchia-2013" TYPE="STUDY">Checchia 2013</LINK>; <LINK REF="STD-Kirbas-2012" TYPE="STUDY">Kirbas 2012</LINK>; <LINK REF="STD-Loukhanov-2011" TYPE="STUDY">Loukhanov 2011</LINK>) our updated review. No new studies were included in the update. The conclusions were not changed.</P>
<P>One new author helped update this version: Fabiano T Barbosa.</P>
<P>We updated the methods section. We updated the risk of bias tool. We included a summary of findings table.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="31" MONTH="7" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Yale University School of Medicine</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<SUMMARY MODIFIED="2014-07-01 10:46:07 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-02-19 15:20:23 +0000" MODIFIED_BY="[Empty name]">Inhaled nitric oxide to treat high blood pressure of the pulmonary vessels after surgery in infants and children with congenital heart disease</TITLE>
<SUMMARY_BODY MODIFIED="2014-07-01 10:46:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence on the effectiveness of inhaled nitric oxide for treatment of high blood pressure in the pulmonary vessels in infants and children born with heart disease.</P>
<P>
<B>Background</B>
</P>
<P>Pulmonary hypertension (PH) is an increase in blood pressure in the pulmonary vessels that affects various patient populations and can cause poor health and a significant number of deaths. PH can reduce cardiac function and precipitate a life-threatening crisis. Congenital heart disease (CHD) is a structural deformity of the heart that exists at birth, and often before birth. PH may arise because of increased pulmonary blood flow and persistent raised pulmonary arterial pressures, or following the use of cardiopulmonary bypass during surgical repair. Inhaled nitric oxide (iNO) is a therapy which causes a selective reduction in the high blood pressure of the pulmonary vessels without decreasing blood pressure in the rest of the body and, therefore, may have a treatment benefit in children with heart disease. In this review, we aimed to assess the benefits and harms of using iNO for postoperative management of PH in children with CHD.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence was current to December 2013. We found four randomized clinical trials involving 210 participants aged from one day to 17 years with PH either in the preoperative (one study) or postoperative period (three studies). Control groups received conventional management therapy (two trials) or nitrogen gas as placebo (two trials). Two trials compared changes in systemic and pulmonary arterial blood pressure and heart rate (haemodynamics). The other two trials compared the number of pulmonary hypertensive crises and deaths, with changes in haemodynamic measurements as secondary outcomes.</P>
<P>
<B>Key results</B>
</P>
<P>We found no differences between the groups of patients who received iNO and those that did not. Two trials reported on deaths before discharge, with none occurring in one of the trials. We observed no differences in the number of deaths (two trials); pulmonary hypertensive crises (one trial); changes in mean pulmonary arterial pressure (three trials), arterial pressure (three trials), or heart rate (HR) (three trials); or changes in oxygenation of the blood (one trial). However, no trials reported long-term deaths or neurodevelopmental disability. In addition, no data were available for analysis of length of hospital stay.</P>
<P>Although iNO has been studied as a postsurgical therapy in children with heart disease in order to assist recovery, this review showed no benefits with its use.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Two trials had a low risk of bias. The quality of the evidence was, however, very low due to the small number of participants and low event rates. All trials utilized different concentrations of iNO, different durations of administration initiated at different times after the operation, and included patients with diverse congenital heart defects necessitating repair.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-02 17:26:51 +0100" MODIFIED_BY="Jane Cracknell">
<ABS_BACKGROUND MODIFIED="2014-07-01 10:29:41 +0100" MODIFIED_BY="[Empty name]">
<P>Nitric oxide (NO) is a prevalent molecule in humans that is responsible for many physiologic activities including pulmonary vasodilation. An exogenous, inhaled form (iNO) exists that mimics this action without affecting systemic blood pressure. This therapy has been implemented in the treatment of pulmonary hypertension. This review examines the efficacy of iNO in the postoperative management of infants and children with congenital heart disease (CHD). The original review was published in 2005, updated in 2008 and again in 2014.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-07-01 11:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the effects of postoperative administration of iNO versus placebo or conventional management, or both, on infants and children with CHD and pulmonary hypertension. The primary outcome was mortality. Secondary outcomes included length of hospital stay; neurodevelopmental disability; number of pulmonary hypertensive crises (PHTC); changes in mean pulmonary arterial pressure (MPAP), mean arterial pressure (MAP), and heart rate (HR); changes in oxygenation measured as the ratio of arterial oxygen tension (PaO<SUB>2</SUB>) to fraction of inspired oxygen (FiO<SUB>2</SUB>); and measurement of maximum methaemoglobin level as a marker of toxicity.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-07-01 10:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>In this updated version we extended the CENTRAL search to 2013, Issue 12 of <I>The Cochrane Library</I>, and MEDLINE and EMBASE through to 1 December 2013. The original search was performed in July 2004 and again in November 2007. We included abstracts and all languages.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-01-02 14:23:22 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomized and quasi-randomized controlled trials comparing iNO with placebo or conventional management, or both. Trials included only children with CHD requiring surgery complicated by pulmonary hypertension.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-02-20 11:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors extracted data. Data were collected on mortality; number of PHTC; changes in MPAP, MAP, HR, and PaO<SUB>2</SUB>:FiO<SUB>2</SUB>; and maximum methaemoglobin level. Data on long-term mortality, neurodevelopmental disability, and length of hospital stay were unavailable. We performed subgroup analysis by method of control (placebo or conventional management).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-02 17:26:51 +0100" MODIFIED_BY="Jane Cracknell">
<P>We reran the searches to December 2013 and identified three new studies. These three studies did not fulfil our inclusion criteria. Therefore, no new studies were included in this updated review. In total four randomized trials involving 210 participants were included in this review. We observed no differences in mortality (OR 1.67, 95% CI 0.38 to 7.30; P = 0.50); PHTC (OR 0.80, 95% CI 0.15 to 4.18; P = 0.79); changes in MPAP (treatment effect -2.94 mm Hg, 95% CI -9.28 to 3.40; P = 0.36), MAP (treatment effect -3.55 mm Hg, 95% CI -11.86 to 4.76; P = 0.40), HR (treatment effect 0.02 bpm, 95% CI -8.13 to 8.18; P = 1.00), or PaO<SUB>2</SUB>:FiO<SUB>2</SUB> (mean difference 17.18, 95% CI -28.21 to 62.57; P = 0.46). There was a significant increase in the methaemoglobin level (mean difference 0.30%, 95% CI 0.24 to 0.36; P &lt; 0.00001) in patients treated with iNO, although levels did not reach toxicity levels. Data from long-term mortality, neurodevelopmental disability, and length of stay were not available. Two trials had a low risk of bias. Very low quality of the evidence was observed considering grading of the outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-01-15 18:59:01 +0000" MODIFIED_BY="[Empty name]">
<P>We observed no differences with the use of iNO in the outcomes reviewed. No data were available for several clinical outcomes including long-term mortality and neurodevelopmental outcome. We found it difficult to draw valid conclusions given concerns regarding methodologic quality, sample size, and heterogeneity.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<BACKGROUND MODIFIED="2014-07-01 11:05:57 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-07-01 10:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>The efficacy of iNO has been extensively investigated and substantiated in the treatment of persistent pulmonary hypertension of the newborn (<LINK REF="REF-Clark-2000" TYPE="REFERENCE">Clark 2000</LINK>; <LINK REF="REF-Kinsella-1992" TYPE="REFERENCE">Kinsella 1992</LINK>; <LINK REF="REF-NINOS-1997" TYPE="REFERENCE">NINOS 1997</LINK>; <LINK REF="REF-Roberts-1992" TYPE="REFERENCE">Roberts 1992</LINK>; <LINK REF="REF-Roberts-1997" TYPE="REFERENCE">Roberts 1997</LINK>). The extreme vasoreactivity of the newborn pulmonary vasculature to inhaled nitric oxide (iNO) has raised the question of whether or not iNO would be an effective treatment for pulmonary hypertension in more diverse populations and clinical scenarios (<LINK REF="REF-Haworth-1984" TYPE="REFERENCE">Haworth 1984</LINK>; <LINK REF="REF-Steudel-1999" TYPE="REFERENCE">Steudel 1999</LINK>). For example, pulmonary hypertension may arise in patients with congenital heart disease (a structural deformity in the heart existing at birth and often before birth) (CHD) characterized by increased pulmonary blood flow. The increased circulation can potentiate remodeling of the vascular bed resulting in persistence of elevated pulmonary arterial pressure, which accelerates the need for operative intervention and potentially complicates postoperative recovery (<LINK REF="REF-Atz-1997" TYPE="REFERENCE">Atz 1997</LINK>; <LINK REF="REF-Wessel-1993" TYPE="REFERENCE">Wessel 1993</LINK>). Pulmonary hypertension can occur in about 50% of CHD cases (<LINK REF="REF-Gorenflo-2010" TYPE="REFERENCE">Gorenflo 2010</LINK>). Endogenous production of nitric oxide is compromised in the early postoperative period and the use of cardiopulmonary bypass during surgical repair can contribute to elevated pulmonary arterial pressures through induction of hypoxaemia, production of microemboli, and excess production of endothelin and thromboxane (<LINK REF="REF-Atz-1997" TYPE="REFERENCE">Atz 1997</LINK>). These factors may result in acute elevations in pulmonary vascular resistance that can impede cardiac output and precipitate life-threatening crises (<LINK REF="REF-Jones-1981" TYPE="REFERENCE">Jones 1981</LINK>; <LINK REF="REF-Wheller-1979" TYPE="REFERENCE">Wheller 1979</LINK>). These events occur postoperatively in approximately 7% of patients with CHD, with an associated mortality rate of about 29% (<LINK REF="REF-Bando-1996" TYPE="REFERENCE">Bando 1996</LINK>). As a result, researchers and clinicians have investigated the use of iNO in the postoperative management of CHD as a means of reducing pulmonary vascular resistance and averting such complications.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-07-01 11:05:57 +0100" MODIFIED_BY="[Empty name]">
<P>Nitric oxide is a molecule that is produced throughout the human body and has a diversity of physiologic actions. One of interest involves its role as a mediator of vasodilation. Within vascular endothelial cells nitric oxide synthase converts L-arginine into nitric oxide (NO). NO then diffuses into vascular smooth muscle where it binds to soluble guanylate cyclase to convert guanosine triphosphate into cyclic guanosine monophosphate (cGMP). The cGMP then mediates vascular smooth muscle relaxation (<LINK REF="REF-Steudel-1999" TYPE="REFERENCE">Steudel 1999</LINK>). Exogenous NO in the form of iNO has a similar mechanism of action on the pulmonary vascular bed. After initiating vascular smooth muscle relaxation the molecule diffuses into the bloodstream where it binds with iron in haemoglobin to form methaemoglobin and is inactivated (<LINK REF="REF-Steudel-1999" TYPE="REFERENCE">Steudel 1999</LINK>). Therefore, the molecule exerts virtually no vasodilatory effect on the systemic circulation. It is this unique property of iNO that has led to the investigation of its use in a myriad of paediatric and adult diseases complicated by pulmonary hypertension (<LINK REF="REF-Nelin-1998" TYPE="REFERENCE">Nelin 1998</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-07-01 10:53:54 +0100" MODIFIED_BY="[Empty name]">
<P>In 1994, Journois et al studied 17 infants with CHD and critical postoperative pulmonary arterial hypertension that was unresponsive to conventional therapies. Initiation of 20 parts per million (ppm) of iNO resulted in a decrease in mean pulmonary arterial pressure (MPAP) in all patients without significant changes in systemic arterial pressure (<LINK REF="REF-Journois-1994" TYPE="REFERENCE">Journois 1994</LINK>). Similar findings were published by Miller et al in a case series of 10 infants with CHD who were administered low dose (2, 10, 20 ppm) iNO in the postoperative period. In infants with a high ratio of pulmonary to systemic arterial pressure there was a significant reduction in mean pulmonary vascular resistance with a subsequent rise in cardiac output (<LINK REF="REF-Miller-1994" TYPE="REFERENCE">Miller 1994</LINK>). A 1995 case series by Beghetti et al also demonstrated a reduction in pulmonary artery pressure and an increase in arterial oxygen saturation without significant alteration in systemic vascular resistance with the use of continuous iNO in the postoperative period (<LINK REF="REF-Beghetti-1995" TYPE="REFERENCE">Beghetti 1995</LINK>). Around the same time, Curran et al demonstrated a minimal benefit of iNO in patients who had undergone atrioventricular canal repair and a significant reduction in pulmonary artery pressure in those with pulmonary hypertension refractory to conventional therapies (that is hyperventilation, hyperoxygenation, and intravenous inotropic support) (<LINK REF="REF-Curran-1995" TYPE="REFERENCE">Curran 1995</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-07-01 10:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>As a result of the findings described above (<LINK REF="REF-Beghetti-1995" TYPE="REFERENCE">Beghetti 1995</LINK>; <LINK REF="REF-Curran-1995" TYPE="REFERENCE">Curran 1995</LINK>; <LINK REF="REF-Journois-1994" TYPE="REFERENCE">Journois 1994</LINK>; <LINK REF="REF-Miller-1994" TYPE="REFERENCE">Miller 1994</LINK>), several investigators undertook randomized controlled trials (RCTs) to more effectively evaluate the use of iNO in the treatment of pulmonary hypertension in the immediate postoperative period for paediatric patients with CHD. There is a clinical guideline recommending iNO for neonates with acute hypoxic respiratory failure (<LINK REF="REF-DiBlasi-2010" TYPE="REFERENCE">DiBlasi 2010</LINK>). Although iNO has been recommended to treat neonates with acute hypoxaemic respiratory failure complicated by pulmonary artery hypertension, its use in other clinical scenarios and patient populations, including infants and children with CHD complicated by pulmonary hypertension, remains uncertain so this systematic review is relevant to answer the research question: what are the effects of postoperative iNO versus placebo or conventional management, or both, on infants and children with CHD?</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>To compare the effects of postoperative administration of iNO versus placebo or conventional management, or both, on infants and children with CHD and pulmonary hypertension. We evaluated:</P>
<OL>
<LI>long-term mortality;</LI>
<LI>mortality prior to hospital discharge;</LI>
<LI>length of intensive care unit or hospital stay;</LI>
<LI>neurodevelopmental disability (a disorder of brain functionthat affects emotion, learning ability, and memory);</LI>
<LI>pulmonary hypertensive crises (PHTC);</LI>
<LI>MPAP, mean arterial (systemic) pressure (MAP), and heart rate (HR);</LI>
<LI>arterial oxygenation (the amount of oxygen in arterial blood) or saturation (non-invasive measurement of oxygen in arterial blood), or both;</LI>
<LI>methaemoglobin level (an abnormal form of haemoglobin that cannot bind oxygen).</LI>
</OL>
<P>We performed subgroup analysis to observe the effects of iNO by method of control (for example placebo versus use of conventional management).<B>
<BR/>
</B>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell">
<SELECTION_CRITERIA MODIFIED="2014-07-01 11:06:53 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-02-20 11:44:53 +0000" MODIFIED_BY="Jane Cracknell">
<P>We evaluated randomized controlled trials (RCTs) and quasi-randomized controlled trials that compared the use of iNO with placebo or conventional management strategies, or both, and included at least one outcome of interest. We considered both parallel and cross-over design trials for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-02-20 11:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>We included infants and children aged one day to 14 years with CHD requiring surgical repair and with evidence of pulmonary hypertension in the pre- or postoperative period. We excluded preterm neonates.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-07-01 11:06:53 +0100" MODIFIED_BY="[Empty name]">
<P>We evaluated the use of iNO at various concentrations ranging from five to 80 ppm when given in the postoperative period.</P>
<P>We evaluated placebo, administered as nitrogen gas (N<SUB>2</SUB>), as a control.</P>
<P>Conventional management included hyperventilation to induce respiratory alkalosis, use of sodium bicarbonate to induce metabolic alkalosis, use of intravenous inotropic and vasodilatory agents, and use of intravenous sedatives and neuromuscular blockade in an attempt to improve pulmonary blood flow (<LINK REF="REF-Whittsett-1999" TYPE="REFERENCE">Whittsett 1999</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-01-07 14:53:57 +0000" MODIFIED_BY="Karen Hovhannisyan">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-01-07 14:54:20 +0000" MODIFIED_BY="Karen Hovhannisyan">
<OL>
<LI>Long-term mortality</LI>
<LI>Mortality prior to discharge</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-01-15 19:05:08 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Length of stay in intensive care unit or hospital</LI>
<LI>Incidence and severity of neurodevelopmental disability</LI>
<LI>Incidence of PHTC</LI>
<LI>Change in MPAP</LI>
<LI>Change in MAP</LI>
<LI>Change in HR</LI>
<LI>Change in ratio of arterial oxygen tension (PaO<SUB>2</SUB>) to fraction of inspired oxygen (FiO<SUB>2</SUB>)</LI>
<LI>Maximum methaemoglobin level</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-07-01 11:09:31 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-07-01 11:09:31 +0100" MODIFIED_BY="[Empty name]">
<P>In our original review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2004, Issue 3), MEDLINE (January 1966 to 1 July 2004) and EMBASE (January 1980 to 1 July 2004) (<LINK REF="REF-Bizzarro-2005" TYPE="REFERENCE">Bizzarro 2005</LINK>). For our first update, the search was extended from 1 July 2004 through to 1 November 2007.</P>
<P>In this latest updated version we searched CENTRAL through to 2013, Issue 12 of <I>The Cochrane Library</I>, and MEDLINE and EMBASE through to 1 December 2013. We used filters to identify RCTs in MEDLINE (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) and EMBASE (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>). We limited the searches to studies in humans. We did not apply any language restrictions during the literature search or for trial inclusion. We included abstracts in this search and handsearched conference abstracts for relevant studies. We retrieved all eligible studies in full text.</P>
<P>The strategy for CENTRAL is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<B>
<BR/>
</B>The strategy for MEDLINE is in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.<B>
<BR/>
</B>The strategy for EMBASE in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.<B>
<BR/>
</B>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-01-23 13:39:08 +0000" MODIFIED_BY="Jane Cracknell">
<P>We searched the reference lists of identified review articles and all included studies in an attempt to identify other potentially eligible studies. We undertook personal communication with primary authors to identify unpublished data, when necessary.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY_SELECTION MODIFIED="2014-07-01 11:10:09 +0100" MODIFIED_BY="[Empty name]">
<P>We utilized the standardized methods for conducting a systematic review as described by The Cochrane Collaboration in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>5.1.0 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Two authors independently read the RCTs identified through searching electronic databases and handsearching of journals. Using the inclusion and exclusion criteria defined above, the authors reached consensus as to which studies were included in the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-07-01 11:10:36 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (MB and IG) independently extracted and collected data on a paper form (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We contacted the authors of trials, when necessary, to obtain raw data not presented in the trial report but necessary for the analysis. We resolved any discrepancies in a consensus meeting.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell">
<P>Two authors (MB and IG) independently assessed the methodologic quality of each included trial following the guidelines described by The Cochrane Collaboration in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.1.0 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). A copy of the form that we used to do this assessment is in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. We resolved any discrepancies in this assessment by a consensus meeting. No third-party intervention was required. We used the 'risk of bias' tool in <LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK> (<LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>). We assessed the risk of bias (when there is an error in the conduct of the trial that could lead to a misleading result) based on the information presented in the papers. We did not contact authors for clarification. We used the following as the assessment criteria.</P>
<SUBSECTION>
<HEADING LEVEL="5">1. Random sequence generation</HEADING>
<P>Low: sequence generation was reported using computer generated random numbers, codes or sealed envelopes. We judged other processes, such as tossing of a coin, as adequate if the whole sequence was generated prior to the start of the trial and if it was performed by a person not otherwise involved in patient recruitment.</P>
<P>High: a system was used which was generated by a non-random approach, e.g. dates, names or identification numbers.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Allocation concealment</HEADING>
<P>Low: if the process that was used prevented patient recruiters, investigators, and participants from knowing the intervention allocation of the next participant to be enrolled in the study.</P>
<P>High: if the allocation method allowed the patient recruiters, investigators, or participants to know the treatment allocation of the next participant to be enrolled in the study.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Blinding of participants and personnel</HEADING>
<P>Low: if participants and personnel were reported as blinded.</P>
<P>High: if participants and personnel were not reported as blinded.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Blinding of outcome assessment</HEADING>
<P>Low: if outcome assessors were reported as blinded.</P>
<P>High: if outcome assessors were not reported as blinded.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Incomplete outcome data</HEADING>
<P>Low: numbers of withdrawals or exclusions per group, with reasons, were provided or if the authors reported no withdrawals or exclusions.</P>
<P>High: numbers of withdrawals or exclusions per group, with reasons, were not provided or if authors did not report reasons for withdrawals or exclusions per group when they were evident.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Selective reporting</HEADING>
<P>Low: if all outcomes were reported.</P>
<P>High: if outcomes were measured but not reported or planned and not measured.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Other bias</HEADING>
<P>Low: if the study appeared to be free of other sources of bias not described in other sections of this table.</P>
<P>High: if the study appeared to be fraudulent or had some other problem not described in other sections of this table.</P>
<P>Unclear: insufficient information was available to consider 'low' or 'high' risk of bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-01 11:26:30 +0100" MODIFIED_BY="[Empty name]">
<P>With respect to data analysis, we employed the standardized methods of the Cochrane Neonatal Review Group (<LINK REF="REF-CNRG-2004" TYPE="REFERENCE">CNRG 2004</LINK>). These included, but were not limited to:</P>
<OL>
<LI>considering which types of study design were appropriate for the review and deciding how to address each type;</LI>
<LI>determining the likely nature of the outcome data (that is, dichotomous, continuous, etc);</LI>
<LI>considering whether it was possible to specify in advance what treatment effect measures were used;</LI>
<LI>deciding how to identify statistical heterogeneity;</LI>
<LI>deciding whether to use random-effects meta-analyses, fixed-effect meta-analyses, or both methods;</LI>
<LI>considering how to assess clinical and methodological diversity (heterogeneity) and whether (and how) to incorporate these into the analysis strategy;</LI>
<LI>deciding how to assess and address the quality of included studies in the analysis; and</LI>
<LI>deciding whether (and how) to seek evidence of possible publication or reporting biases.</LI>
</OL>
<P>We identified pertinent data from trials of both parallel (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>) and cross-over (<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>) design. When the outcome of interest included only dichotomous data from parallel trials, we calculated an odds ratio (OR) with 95% confidence interval (CI) using a fixed-effect model. When the outcome of interest included only continuous data from parallel trials, we calculated a mean difference (MD) with 95% CI using a fixed-effect model. When the outcome of interest included data from both parallel and cross-over trials, we employed the generic inverse variance method to analyse these combinations of data. Before any of these methods could be utilized, we collected and assessed individual patient data. We collected baseline measurements of MPAP, MAP, HR, and the ratio of PaO<SUB>2</SUB>:FiO<SUB>2 </SUB>for each individual patient and compared them with measurements taken at the completion of therapy. We then calculated a mean change score with standard deviation for both the treatment and control groups. We calculated a reduction in any of the above outcomes from baseline as a negative change score, whereas we calculated an increase from baseline as a positive change score. Individual patient data were available from <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; and we obtained data direct from the authors of <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>. When necessary, we calculated MPAP from available individual patient pulmonary systolic and diastolic pressures. In <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>, individual patient data were presented as the baseline MPAP of each patient and the subsequent per cent change in MPAP from baseline after initiation of therapy. Using the per cent change from the initial MPAP, the final MPAP and change score could be calculated for each patient. For the change in HR and MAP in <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>, we calculated a change score from the available baseline and post-treatment mean values. To calculate the standard deviation (SD) we utilized the methods described by The Cochrane Collaboration in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>5.1.0 (Section 7.7.3.2) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). First, we imputed correlation coefficients for both the treatment and control groups from <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>. We chose this study because it was most similar to <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> (the <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> trial being of cross-over design). Next, we calculated the SD for both the control and treatment group utilizing the corresponding correlation coefficient and the available data.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-01-23 13:53:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>We did not have any unit of analysis issues.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-01-23 14:04:13 +0000" MODIFIED_BY="Jane Cracknell">
<P>We contacted the trial authors to clarify missing or unclear data when necessary. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-07-01 11:29:09 +0100" MODIFIED_BY="[Empty name]">
<P>We performed testing for heterogeneity of treatment effect using a Chi<SUP>2</SUP> test. We also employed the I<SUP>2</SUP> statistic and Chi<SUP>2</SUP> test to measure the degree of inconsistency among results. We considered data highly suspicious if we identified an I<SUP>2 </SUP>value greater than 50% and, under these circumstances, data were reanalysed using a random-effects model.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-02-20 11:55:31 +0000" MODIFIED_BY="Jane Cracknell">
<P>We planned to assess publication bias using a funnel plot (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) if more than nine studies were included in the meta-analysis. The funnel plot has an inverted funnel shape if publication bias is absent; funnel plots are examined visually and through Egger's test to test asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell">
<P>In order to combine and analyse data from both parallel and cross-over trials, we first calculated treatment effects and 95% CIs for both the continuous and dichotomous data. For continuous data, we calculated an MD with 95% CI using a fixed-effect model for each outcome described. For dichotomous data, we calculated an OR with 95% CI using a fixed-effect model. Next, we calculated a standard error (SE) for each outcome of interest using the 95% CI and a value from the t-distribution as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>5.1.0 (Section 7.7.7.2) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Now, with the available treatment effect and SE for each outcome of interest, we could enter data into the generic inverse variance model for analysis. We entered dichotomous data presented in the form of an OR as logarithms as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.1.0 (Section 7.7.2) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Because the generic inverse variance model output omits the number of data points contributed by each trial, we have included this information in the 'Additional tables' section of the review (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>;). We performed the analysis in <LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK> (<LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-07-01 11:32:24 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to do subgroup analysis based on method of control as described above in the <LINK TAG="OBJECTIVES" TYPE="SECTION">Objectives</LINK> (placebo or conventional management).</P>
<P>We estimated statistical heterogeneity through the Chi<SUP>2</SUP> test and I<SUP>2</SUP> statistic. Potential sources of heterogeneity among these studies included differential exposure intensity (for example dosing of iNO and length of treatment), differential treatment of control groups (for example placebo versus conventional management), and host factors (for example age, type of underlying cardiac disease). We planned to explore some of these via subgroup analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-01-23 14:16:05 +0000" MODIFIED_BY="Jane Cracknell">
<P>We performed sensitivity analyses, when possible, by excluding trials of lower methodologic quality and reanalysing the data.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-01 12:11:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-07-01 11:46:10 +0100" MODIFIED_BY="[Empty name]">
<P>The details concerning each individual study are addressed in the tables <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-07-01 11:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>In our original review we identified six trials that were relevant to our topic of interest (<LINK REF="REF-Bizzarro-2005" TYPE="REFERENCE">Bizzarro 2005</LINK>). We included four RCTs in the review (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>; <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>) and excluded two studies (<LINK REF="STD-Argenziano-1998" TYPE="STUDY">Argenziano 1998</LINK>; <LINK REF="STD-Matsui-1997" TYPE="STUDY">Matsui 1997</LINK>). In our first update (search to November 2007) we identified two relevant studies and excluded both (<LINK REF="STD-Khazin-2004" TYPE="STUDY">Khazin 2004</LINK>; <LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>). For this updated search (from November 2007 to 1 December 2013) we excluded 49 studies considering the inclusion criteria and identified three additional relevant trials (<LINK REF="STD-Checchia-2013" TYPE="STUDY">Checchia 2013</LINK>; <LINK REF="STD-Kirbas-2012" TYPE="STUDY">Kirbas 2012</LINK>; <LINK REF="STD-Loukhanov-2011" TYPE="STUDY">Loukhanov 2011</LINK>) but none met out inclusion criteria. For a summary of the search see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-07-01 11:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>Three of the trials were of parallel design (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>) while the fourth employed a cross-over design (<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>). However, using the recommendations from The Cochrane Collaboration for evaluation of a cross-over trial (<LINK REF="REF-Alderson-2002" TYPE="REFERENCE">Alderson 2002</LINK>), the authors concluded that the inclusion of this study into the review was valid. The details of the participants and interventions can be found in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Each of the four trials included in the review evaluated the use of postoperative iNO in infants and children with CHD necessitating repair. All included participants were identified as having pulmonary hypertension either in the preoperative or postoperative period. In three of the studies (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>) postoperative pulmonary hypertension was used as a criterion either for inclusion or for a separate subgroup analysis. One of the RCTs (<LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>) utilized preoperative diagnosis as part of the entry criteria into the trial but did not comment on the presence or absence of postoperative pulmonary hypertension in individual included participants.</P>
<P>In each RCT children were the primary patient population studied. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> included 35 patients aged 2 days to 6.5 years. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> included 44 patients aged 1 day to 20 years (and 2 adults). <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> included 12 patients with an age range from 1 month to 17 years (1 adult). <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> did not specifically list the age range of their patient population but instead commented on inclusion of 124 patients with a median age of 3 months in the treatment group and 2 months in the control group. We excluded data on adult patients (defined as greater than or equal to 17 years of age) from the analysis.</P>
<P>The RCTs differed with respect to the method of treatment utilized in the control groups. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> compared the use of iNO with 'conventional treatment' in the control group. No strict criteria or definition of 'conventional management' were utilized in this trial and management of the control group was instead left to the discretion of the attending cardiothoracic surgeon. <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> employed a cross-over method with patients randomized to receive either iNO in the treatment group or hyperventilation as the treatment comparison in the control group (often part of the conventional management protocol). This trial utilized a 30-minute washout period between treatments. With the exception of the intervention, patient management was similar in both groups. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> initiated iNO in the treatment group versus placebo in the control group, although underlying conventional therapies (such as hyperventilation and the use of inotropes) were maintained in both groups.</P>
<P>The trials also differed with respect to onset and duration of iNO therapy in the postoperative period. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> initiated iNO or placebo therapy immediately after patients were removed from cardiopulmonary bypass and continued treatment for a total of 20 minutes. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> initiated therapy upon the patient's arrival in the intensive care unit (ICU) and continued treatment until extubation, although data collection occurred at one hour after initiation of therapy. <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> used a cross-over study design comparing iNO with hyperventilation. Treatment was initiated at a mean of 8.5 hours postoperation (range 4 to 40 hours) and each treatment was given for a period of 30 minutes. <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> initiated therapy just after completion of surgery and continued iNO or placebo for a maximum of seven days.</P>
<P>The concentration of iNO utilized also differed among studies. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> initiated iNO at 80 ppm while <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> initiated 20 ppm. <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> initiated a 5 ppm concentration of iNO for 15 minutes and then 40 ppm for the remaining 15 minutes of treatment (although data were presented only for outcomes on 40 ppm). <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> initiated iNO at 10 ppm and continued the use of this concentration throughout the duration of the study.</P>
<P>Primary outcomes differed slightly among the RCTs as well. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> compared changes in haemodynamics (MPAP, MAP, HR) as their primary outcomes of interest. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> compared the number of PHTC and the incidence of mortality in each group as their primary outcomes of interest. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> compared changes in haemodynamic measurements as secondary outcomes of interest.</P>
<P>Data presentation differed among the RCTs included in this review. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> presented individual data whereas <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> presented group data. Individual data were collected from Dr Ronald Day so that certain outcomes of interest, specifically MPAP and MAP, could be calculated and included. With respect to <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>, most data were presented as group data in the form of median values and interquartile ranges. We thus assumed that the data were skewed, making it difficult to calculate the necessary means and SDs required for inclusion in the analysis. Attempts to obtain the data from the authors in a form that could be utilized were unsuccessful.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-07-01 11:46:10 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded seven studies during the review process. Of the excluded studies, <LINK REF="STD-Matsui-1997" TYPE="STUDY">Matsui 1997</LINK> was listed in CENTRAL but was not an RCT; <LINK REF="STD-Argenziano-1998" TYPE="STUDY">Argenziano 1998</LINK> was an RCT on the topic of interest but utilized only an adult patient population; <LINK REF="STD-Khazin-2004" TYPE="STUDY">Khazin 2004</LINK> compared iNO with milrinone, not placebo or conventional management, and analysed the combined effects of the two agents on pulmonary hypertension in the patient population of interest for this review; <LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK> compared citrulline, an NO precursor, with placebo in the patient population of interest. <LINK REF="STD-Loukhanov-2011" TYPE="STUDY">Loukhanov 2011</LINK> and <LINK REF="STD-Kirbas-2012" TYPE="STUDY">Kirbas 2012</LINK> compared the effects of iNO versus aerosolized iloprost on pulmonary hypertension in the patient population of interest within the first 72 hours post-bypass. <LINK REF="STD-Checchia-2013" TYPE="STUDY">Checchia 2013</LINK> compared the effects of iNO versus placebo delivered to the membrane oxygenator only during cardiopulmonary bypass in children undergoing repair of tetralogy of Fallot. The details of all exclusions can be found in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-01 11:53:43 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized and quasi-randomized controlled trials in this review (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The bias domains are presented in the 'risk of bias&#8217; summary figure and in the 'risk of bias&#8217; graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Two studies had low risk of bias (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>). We assessed methodological quality based on the following criteria.</P>
<ALLOCATION MODIFIED="2014-07-01 11:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> did not list specific techniques for randomization. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> employed a "blind draw from sequential groups containing six assignments". No further detail was given as to who, the investigators or a separate participant, actually performed the draw and assignment. Finally, <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> employed a computer-based randomization program to assign patients to the treatment or control group.</P>
<P>Concealment of allocation was adequate in <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> and <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> as blinding of randomization was likely to have been preserved through the methods of randomization. Concealment was unclear in <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> and <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> as, since no explicit details about methods of randomization were provided, the review authors had no way of confirming whether or not concealment of allocation was preserved.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-07-01 11:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> described adequate blinding of treatment by stating, "The operative team (surgeons, anaesthesiologists, and echocardiographies) were blinded to the treatment assigned". <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> also described adequate blinding of treatment as the treatment and placebo gas "were masked with locked opaque covers" and adjusted by a non-clinical investigator. In the trials by <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> and <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>, however, the investigators were unblinded with respect to treatment, allowing for the possibility of performance bias. Both trials essentially employed iNO versus conventional therapy (hyperventilation in the Morris trial). Without the use of a placebo gas the investigators could not maintain blinding.</P>
<P>
<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> and <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> were unblinded with respect to outcome assessment, allowing for the introduction of detection bias into their analyses. <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> preserved blinded outcome assessment whereas <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> did not comment on this level of blinding.</P>
<P>We based the overall assessment of methodologic quality primarily on the quality of concealment of allocation. We also factored patient, physician, and outcome assessor blinding into the assessment. Based on this technique for evaluation, we found <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> to be of the highest methodologic quality with a low risk of bias. We found <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> to be of above average quality with a low to moderate risk of bias. Although concealment of allocation was adequate, a lack of patient, physician, and outcome assessor blinding made the potential for performance and detection bias likely. We assessed <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> to be of average methodologic quality due to lack of concealment of allocation. We determined <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> to be of poor methodologic quality, particularly for the lack of concealed allocation and blinding. We attempted to assess the trials of higher quality (for example <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> and <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>) separately in a sensitivity analysis but could not do so due to sample size. These issues of methodologic quality are addressed in further detail in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section below.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-07-01 11:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> initially randomized 39 patients but only obtained results from 35 patients as four were excluded due to technical problems (three for failure to place a necessary pulmonary artery catheter and one due to equipment problems). Which group these patients were initially assigned to was not described. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> enrolled 44 patients (two patients were actually enrolled on two separate occasions for separate surgical procedures) and followed all to completion of the study. Four patients initially assigned to the control group were allowed to cross over and receive iNO if conventional therapy failed. These were excluded from the analysis. <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> enrolled 12 patients and followed all to completion. <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> initially enrolled 124 infants, all of whom completed the study. Intention to treat was preserved in all trials.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-02-18 17:59:33 +0000" MODIFIED_BY="[Empty name]">
<P>All trials reported all expected outcomes. There was no risk of bias identified in any of the studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-07-01 11:53:43 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies appeared to be free of other sources of bias (<LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>; <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>). <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> did not analyse patients with initial low pulmonary arterial pressure and excluded patients who developed an increase in pressure after they were already excluded from the study. <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> did not measure the methaemoglobin level in all patients who received iNO.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-01 12:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> for the main comparison.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Inhaled nitric oxide versus placebo or conventional treatment, or both</HEADING>
<P>No data were available on several outcomes that we had hoped to include in our analysis. In particular, no long-term follow-up data were available from any of the four trials and thus we could not assess the outcomes of long-term mortality and neurodevelopmental disability. In addition, no data on length of hospital stay were available for analysis from any of the trials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Long-term mortality</HEADING>
<P>No data were available for this outcome from any of the trials included in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality prior to discharge</HEADING>
<P>Mortality was reported in two of the four trials included in this review (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>). <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> reported no deaths in either the treatment or control group whereas <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> observed five deaths out of the 63 children in the treatment group and three of 61 in the control group (although only one death in each group was believed to be related to a PHTC). The data presented were from parallel trials only and, therefore, we decided to calculate an OR. The analysis showed no statistically significant difference with respect to mortality between the two groups (OR 1.67, 95% CI 0.38 to 7.30; P = 0.50) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of stay in intensive care unit or hospital</HEADING>
<P>No data were available for this outcome from any of the trials included in the review.<B>
<I> </I>
</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and severity of neurodevelopmental disability</HEADING>
<P>No data were available for this outcome from any of the trials included in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mean number of pulmonary hypertensive crises (PHTC)</HEADING>
<P>This outcome was reported only in <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> with 3 PHTC out of the 18 children in the treatment group and 4 PHTC out of the 20 children in the control group. The data were from a parallel trial and we calculated an OR. The analysis showed no significant difference with respect to the absolute number of PHTC in the treatment versus the control groups (OR 0.80, 95% CI 0.15 to 4.18; P = 0.79) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in mean pulmonary arterial pressure (MPAP) change score</HEADING>
<P>This outcome was initially reported in two of the four trials (<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>) and recorded, but not reported, in a third (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>). As a result, we obtained and analysed the raw, individual patient data from the investigators. A reduction in MPAP was considered a favourable outcome.</P>
<P>Overall, the meta-analysis revealed no significant change in MPAP between iNO and control (treatment effect -2.94 mm Hg, 95% CI -9.28 to 3.40; P = 0.36). The level of heterogeneity (I<SUP>2 </SUP>= 45%) was just below that considered significant (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in mean arterial pressure (MAP) change score</HEADING>
<P>This outcome was reported in three of the included trials (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>). A reduction in MAP was considered an unfavourable outcome whereas no change or an increase in MAP from baseline was considered favourable.</P>
<P>Overall, the meta-analysis revealed no significant difference in effect between the two groups (treatment effect -3.55 mm Hg, 95% CI -11.86 to 4.76; P = 0.40). We observed no heterogeneity (I<SUP>2 </SUP>= 0%) between trials (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in heart rate (HR) change score</HEADING>
<P>This outcome was reported in three of the four trials (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>). A reduction in HR, assuming constant stroke volume, was considered an unfavourable outcome as compared to no change or an increase from baseline.</P>
<P>Overall, the meta-analysis did not show a significant difference in overall effect in either group (treatment effect 0.02 bpm, 95% CI -8.13 to 8.18; P = 1.00). We observed no heterogeneity between studies (I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in PaO<SUB>2</SUB>:FiO<SUB>2 </SUB>change score</HEADING>
<P>Only one parallel trial (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>) included this outcome. An increase in this ratio was considered a favourable outcome and indicative of improved arterial oxygenation. The trial observed no significant change in the ratio with the use of iNO as compared with control (MD 17.18, 95% CI -28.21 to 62.57; P = 0.46) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Maximum methaemoglobin level</HEADING>
<P>This outcome was reported in only one of the four studies (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>). An increase in methaemoglobin level was considered an unfavourable outcome. These data were from a parallel trial and thus we calculated a weighted mean difference. Overall, there was a significantly elevated methaemoglobin level in the iNO group when compared to control (MD 0.30%, 95% CI 0.24 to 0.36; P &lt; 0.00001). However, the maximum methaemoglobin level did not approach toxicity levels (&gt; 10%) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inhaled nitric oxide versus conventional management</HEADING>
<P>This analysis utilized data from <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>. These investigators compared the use of iNO to conventional therapies in the management of postoperative pulmonary hypertension.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mortality prior to discharge</HEADING>
<P>Data from <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> revealed no deaths in either treatment or control groups and so no analysis was performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mean number of pulmonary hypertensive crises (PHTC)</HEADING>
<P>The analysis revealed no significant difference in the number of PHTC experienced by the treatment and control groups (the same data as that presented in <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in MPAP change score</HEADING>
<P>This analysis included data from <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>. We observed no statistically significant change in MPAP (treatment effect -1.14 mm Hg, 95% CI -8.87 to 6.59; P = 0.77) and a significant amount of heterogeneity between studies (I<SUP>2 </SUP>= 58%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in MAP change score</HEADING>
<P>The data analysis revealed no significant difference in the change in MAP between treatment and control groups (treatment effect -1.94 mm Hg, 95% CI -11.23 to 7.35; P = 0.68). We observed no heterogeneity between studies on this outcome (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in HR change score</HEADING>
<P>This analysis was again comprised of data from <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>. There was no significant difference observed in the change in HR between groups (treatment effect -0.37 bpm, 95% CI -8.85 to 8.10; P = 0.93). No heterogeneity was observed (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in PaO<SUB>2</SUB>:FiO<SUB>2 </SUB>change score</HEADING>
<P>This outcome included data only from <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>, which was the same data as presented in <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>
<I>.</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Maximum methaemoglobin level</HEADING>
<P>This outcome was reported in only one study (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>), which was the same data as presented in <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inhaled nitric oxide versus placebo</HEADING>
<P>This analysis separated those trials utilizing placebo in the control group from those which initiated conventional therapy (that is hyperventilation, pressor support, etc). We included <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> and <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mortality prior to discharge</HEADING>
<P>
<LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> reported on this outcome. Since the only other trial (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>) that also reported mortality had no events the results were the same as previously described (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in MPAP change score</HEADING>
<P>We utilized data from <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> in this analysis and observed no significant change in MPAP in the treatment group compared with placebo (treatment effect -9.15 mm Hg, 95% CI -20.70 to 2.40; P = 0.12) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in MAP change score</HEADING>
<P>We utilized data from <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> in this analysis and observed no significant change in MAP with the use of iNO (treatment effect -10.00 mm Hg, 95% CI -28.60 to 8.60; P = 0.29) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Difference in HR change score</HEADING>
<P>We utilized data from <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> in this analysis. We observed no significant difference between the treatment and control groups with respect to change in HR (treatment effect 5.00 bpm, 95% CI -24.99 to 34.99; P = 0.74) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We considered<B>
<I> </I>
</B>
<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> to be of highest methodologic quality. <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> only reported on the outcome mortality prior to discharge. This was the same data as presented in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, which showed no significant difference between groups (P = 0.50). No other sensitivity analyses could be performed.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<SUMMARY_OF_RESULTS MODIFIED="2014-07-01 12:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>A substantial amount of data have been published favouring the use of iNO in the treatment of neonates with persistent pulmonary hypertension (<LINK REF="REF-Clark-2000" TYPE="REFERENCE">Clark 2000</LINK>; <LINK REF="REF-Kinsella-1992" TYPE="REFERENCE">Kinsella 1992</LINK>; <LINK REF="REF-NINOS-1997" TYPE="REFERENCE">NINOS 1997</LINK>; <LINK REF="REF-Roberts-1992" TYPE="REFERENCE">Roberts 1992</LINK>; <LINK REF="REF-Roberts-1997" TYPE="REFERENCE">Roberts 1997</LINK>). These findings have encouraged research in other patient populations demonstrating pulmonary hypertension. In children with CHD, elevated pulmonary arterial pressures may complicate postoperative recovery and, in some instances, potentiate life-threatening crises. As a result, safe and effective therapeutic intervention has been sought. This review evaluated the therapeutic role of iNO in the postoperative management of infants and children with CHD.</P>
<P>The four RCTs included in this review focused on two major types of primary objectives. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> evaluated the postoperative effect of iNO on short-term clinical outcomes (for example mortality, number of life-threatening crises, improvements in oxygenation), while <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> and <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> evaluated the physiologic changes (for example MPAP, MAP, HR) that occur with the use of iNO. Unfortunately, no data were collected to evaluate the long-term outcomes of morbidity (for example neurodevelopmental disability) and mortality.</P>
<P>In analysing the primary outcome of mortality prior to discharge, we observed no statistically significant difference between the treatment and control groups. These findings are based on data from two trials (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>), one of which (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>) observed no deaths in either group studied. While these findings indicate no substantial difference in mortality between those children treated with iNO and those treated with placebo or conventional therapy, the relatively small sample size (N = 162) and low incidence of PHTC-related postoperative deaths (N = 2) must be considered when attempting to draw general conclusions. A similar problem arises in the analysis of secondary outcomes. While no differences were observed between treatment and control groups with respect to the number of PHTC in the postoperative period, the data are based on one RCT (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>).</P>
<P>
<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK> and <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK> focused on changes in haemodynamics in the postoperative period. <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK> and <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK> also documented these changes but as secondary outcomes. As a selective pulmonary vasodilator, one might expect iNO to cause a significant decrease in MPAP when compared with placebo. When we examined this outcome we observed no statistically significant change in MPAP with the use of iNO versus control. Similarly, no significant differences were observed between groups with respect to changes in MAP or HR. Subgroup analysis by method of control also demonstrated no significant differences in haemodynamics with either method of control, but valid interpretation of these findings was difficult based on the small numbers of patients analysed in each group.</P>
<P>The ratio PaO<SUB>2</SUB>:FiO<SUB>2</SUB> is a measure of oxygenation and a positive change in this ratio implies an improvement. This outcome was measured in only one trial (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>) and revealed no significant difference between treatment and control groups. It is unclear whether this lack of improvement is related to ineffectiveness of iNO to promote increased pulmonary blood flow.</P>
<P>The maximum methaemoglobin level, a measure of toxicity, was reported only in <LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>. In the analysis there was a significant increase in this measure in the iNO group as compared to the control group, which one would expect as methaemoglobin, a byproduct of iNO, should not be elevated in the control group. What is more important is whether or not the maximum level approached toxicity (&gt; 10%), which it did not.</P>
<P>Thus, from this analysis it appears that the postoperative use of iNO does not result in a significant reduction in mortality and the number of PHTC, nor does its use appear to significantly alter haemodynamics or result in any improvement in other clinically relevant outcomes such as arterial oxygenation. However, the validity of these conclusions needs to be examined further.</P>
<P>The major limitation of this review relates to sample size which, when data were available, affected both the precision and interpretability of the results. When assessing one of our primary outcomes, mortality prior to discharge, data were available from only two trials (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>) with only two deaths observed. Similarly, when assessing the number of PHTC, data were only available from one trial (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>). Furthermore, data on long-term mortality, neurodevelopmental disability, and length of stay were simply not available. In addition, there was significant potential for selection bias in two of the four trials (<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>) and heterogeneity between studies given that all trials utilized different concentrations of inhaled nitric oxide, different lengths of administration of therapy, and included patients with diverse congenital heart lesions and of various ages.</P>
<P>The strengths of the review were that it included four RCTs. Also, we were able to obtain data on the majority of our outcomes of interest, which included individual patient data in most cases. Lastly, while there was concern about heterogeneity, no significant heterogeneity was observed between studies when analysing the majority of outcomes of interest.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-07-01 12:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>Several factors exist within and amongst the included trials that make an accurate meta-analysis with a definitive conclusion difficult. The first area of concern to be addressed is with respect to the methodologic quality of the included studies. The trial of highest methodologic quality (<LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>) only included data with respect to mortality that could be included in the analysis. Of the three remaining trials, we assessed only one (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>) as being of relatively high methodologic quality based on concealment of allocation. Thus, the potential for selection bias is likely in the remaining two trials (<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>; <LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>). Although the results of this meta-analysis do not appear to show any significant clinical benefit of iNO to treat pulmonary hypertension in children with CHD, any significant clinical harm is not identified in this systematic review.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-07-01 12:29:59 +0100" MODIFIED_BY="[Empty name]">
<P>We considered the quality of the evidence using the measurement of risk of bias. There was one study that had a low risk of bias in all domains (<LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>). Random sequence generation, allocation concealment, incomplete outcome data, and selective reporting were not assessed as high risk of bias in all included studies. Small sample sizes affected precision of the results. There was not substantial heterogeneity between the studies that analysed the majority of outcomes of interest.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-07-01 12:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>Factors that also contribute to potential biases are lack of blinding to the intervention (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>) and lack of blinded outcome assessment, or failure to report this procedure, in all three studies. Therefore, the potential for the introduction of bias into the trials and subsequently the analysis is likely. We attempted to address this issue via sensitivity analysis, by evaluating only those trials of high methodologic quality (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>; <LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>). Unfortunately the only outcome that could be assessed, given the lack of individual data from one trial (<LINK REF="STD-Miller-2000" TYPE="STUDY">Miller 2000</LINK>), was mortality prior to discharge.</P>
<P>Also of concern is the relatively sparse number of patients included in the majority of the studies, as documented in the 'Additional tables' section of this review (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). A total of 73 outcomes collected from 62 infants and children (iNO group = 34, placebo and conventional management groups = 39) were included (the discrepancy arises as a result of the cross-over design of <LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>). A possible explanation for the relatively small numbers of participants lies in the fact that we are dealing with a very specific population with CHD necessitating repair and demonstrating elevated pulmonary arterial pressures. The small sample sizes are reflected in the wide CIs seen in the analysis and, as a result, compromise the precision of the review.</P>
<P>Another serious problem with the meta-analysis concerns the potential heterogeneity that exists among the included investigations. All four trials utilized different concentrations of iNO, different lengths of administration of therapy, and included patients with diverse congenital heart lesions and of various ages. While the I<SUP>2</SUP> statistic for heterogeneity is not statistically significant in most cases, the potential is apparent. An attempt to deal with this is presented in the form of the subgroup analysis on method of control. Unfortunately, further subgroup analyses based on host factors and concentration of iNO administered could not be performed due to small sample sizes and missing individual patient data. Therefore, although no significant differences were observed with the use of iNO in this patient population, there is the potential for heterogeneity and bias that compromise the results of the review and make it impossible to draw any definitive conclusions at the present time.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>A Cochrane systematic review considered inhaled nitric oxide for respiratory failure in infants born at or near term (<LINK REF="REF-Finer-2009" TYPE="REFERENCE">Finer 2009</LINK>). The authors found a statistically significant reduction in death or need for extracorporeal membrane oxygenation (ECMO) with the use of iNO (Mantel-Hanzel risk ratio 0.65, 95% CI 0.55 to 0.76). This paper did not include studies from our review as it focused on infants with acute respiratory disease, not postoperative patients with CHD, and assessed different outcomes of interest including the need for ECMO.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-01-15 19:32:34 +0000" MODIFIED_BY="[Empty name]">
<P>The results of this meta-analysis do not appear to show any significant clinical benefit with the use of postoperative iNO to treat pulmonary hypertension in children with CHD. We have observed no differences with respect to mortality, number of PHTC, arterial oxygenation, or changes in haemodynamics with the use of postoperative iNO. There are no data to determine the effects of treatment with iNO on length of stay in an ICU or hospital, long-term mortality, or neurodevelopmental disability. Furthermore, the relatively sparse patient population and the potential biases that may be present as a result of problems with the methodology of the trials make it impossible to draw any valid conclusions about treatment effect at this time.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-01-15 19:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>It is evident from this review that more data from randomized controlled trials of high methodologic quality are necessary in order to appropriately evaluate the therapeutic potential of iNO in this clinical setting. Also, although the outcomes reviewed in these trials are of clinical importance, more relevant outcomes need to be assessed. In particular, additional patient data with respect to mortality; length of ICU and hospital stay, or both; neurodevelopmental outcomes; and measures of oxygenation necessitate further investigation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-01 12:38:03 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Dr Mathew Zacharias, Professor Marcus Müllner, Dr Tom Pedersen, Dr Karen Burns, Dr Keith Barrington, and The Cochrane Heart Group peer reviewers and consumer panel for their help and editorial advice during the preparation of our protocol. We would also like to thank Dr Mathew Zacharias, Dr Keith Barrington, Dr Ronald Day, Dr Robert Tulloh, Professor Nathan Pace, Kathie Godfrey, Janet Wale and Jane Cracknell for their assistance and editorial comments during the preparation of the original published review (<LINK REF="REF-Bizzarro-2005" TYPE="REFERENCE">Bizzarro 2005</LINK>).</P>
<P>We would like to thank Dr Ronald Day for the contribution of his individual patient data for analysis and inclusion in this review.<BR/>
<B>
<BR/>
</B>We would also like to thank Dr Michael Bracken for his instruction in the concepts and principles of evidence-based medicine and the preparation of a systematic review in addition to his statistical assistance with the analyses of data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-02-20 11:37:00 +0000" MODIFIED_BY="Jane Cracknell">
<P>Matthew Bizzarro: none known</P>
<P>Ian Gross: none known</P>
<P>Fabiano T Barbos: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-07-01 12:39:57 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Matthew Bizzarro (MB), Dr Ian Gross (IG) and Fabian T Barbosa (FTB) updated this review.</P>
<P>Conceiving the review: MB<BR/>Co-ordinating the review: FTB<BR/>Undertaking manual searches: MB<BR/>Screening search results: MB, IG<BR/>Organizing retrieval of papers: MB<BR/>Screening retrieved papers against inclusion criteria: MB<BR/>Appraising quality of papers: MB, IG, FTB<BR/>Abstracting data from papers: MB<BR/>Writing to authors of papers for additional information: MB<BR/>Providing additional data about papers: MB<BR/>Obtaining and screening data on unpublished studies: MB<BR/>Data management for the review: MB<BR/>Entering data into Review Manager (<LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>): FTB<BR/>RevMan statistical data: MB, FTB<BR/>Other statistical analysis not using RevMan: MB<BR/>Double entry of data: MB, FTB<BR/>Interpretation of data: MB, IG<BR/>Statistical inferences: MB<BR/>Writing the review: FTB<BR/>Securing funding for the review: N/A<BR/>Performing previous work that was the foundation of the present study: MB<BR/>Guarantor for the review (one author): MB<BR/>Person responsible for reading and checking review before submission: MB, IG, FTB<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-07-01 12:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>February 2014</P>
<OL>
<LI>One new author was included (Fabiano T Barbosa).</LI>
<LI>We updated the methods section. Risk of bias tools were included in this updated review and items analysed before in 'risk of bias in included studies' (method of randomization, concealment of allocation, blinding of intervention, completeness of follow up, and blinded outcome assessment) were renamed to random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias.</LI>
<LI>Items of the risk of bias tables were reanalysed.</LI>
<LI>We included a summary of findings table.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-01-02 14:30:36 +0000" MODIFIED_BY="[Empty name]">
<P>None</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-01 12:57:47 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-07-01 12:53:26 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-30 14:51:06 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Day-2000" NAME="Day 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Day RW, Hawkins JA, McGough EC, Crezee KL, Orsmond GS</AU>
<TI>Randomized controlled study of inhaled nitric oxide after operation for congenital heart surgery</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2000</YR>
<VL>69</VL>
<NO>6</NO>
<PG>1907-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10892945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2000" NAME="Miller 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS</AU>
<TI>Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9240</NO>
<PG>1464-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11081528"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-2000" NAME="Morris 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morris K, Beghetti M, Petros A, Adatia I, Bohn D</AU>
<TI>Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<NO>8</NO>
<PG>2974-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10966281"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1998" NAME="Russell 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Russell IA, Zwass MS, Fineman JR, Balea M, Rouine-Rapp K, Brook M et al</AU>
<TI>The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998</YR>
<VL>87</VL>
<NO>1</NO>
<PG>46-51</PG>
<MD>PMID: 9661544</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-01 12:53:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Argenziano-1998" NAME="Argenziano 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argenziano M, Choudhri AF, Moazami N, Rose EA, Smith CR, Levin HR et al</AU>
<TI>Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>2</NO>
<PG>340-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9485226"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Checchia-2013" MODIFIED="2014-07-01 12:50:54 +0100" MODIFIED_BY="[Empty name]" NAME="Checchia 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-07-01 12:50:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Checchia PA, Bronicki RA, Muenzer JT, Dixon D, Raithel S, Gandhi SK et al</AU>
<TI>Nitric oxide delivery during cardiopulmonary bypass reduces postoperative morbidity in children--a randomized trial</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2013</YR>
<VL>146</VL>
<NO>3</NO>
<PG>530-6</PG>
<IDENTIFIERS MODIFIED="2014-02-19 11:26:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-19 11:26:24 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 23228403"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khazin-2004" NAME="Khazin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khazin V, Kaufman Y, Zabeeda D, Medalion B, Sasson L, Schachner A et al</AU>
<TI>Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>2</NO>
<PG>156-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15073704"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirbas-2012" MODIFIED="2014-07-01 12:51:59 +0100" MODIFIED_BY="[Empty name]" NAME="Kirbas 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-01 12:51:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirbas A, Yalcin Y, Tanrikulu N, Gürer O, Isik O</AU>
<TI>Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery</TI>
<SO>Cardiology Journal</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>4</NO>
<PG>387-94</PG>
<IDENTIFIERS MODIFIED="2014-02-19 11:26:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-19 11:26:45 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="22825900"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loukhanov-2011" MODIFIED="2014-07-01 12:52:41 +0100" MODIFIED_BY="[Empty name]" NAME="Loukhanov 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-07-01 12:52:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loukanov T, Bucsenez D, Springer W, Sebening C, Rauch H, Roesch E et al</AU>
<TI>Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery</TI>
<SO>Clinical Research in Cardiology</SO>
<YR>2011</YR>
<VL>100</VL>
<NO>7</NO>
<PG>595-602</PG>
<IDENTIFIERS MODIFIED="2013-12-30 15:58:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-30 15:58:58 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="PMID: 21318559"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsui-1997" MODIFIED="2014-07-01 12:53:02 +0100" MODIFIED_BY="[Empty name]" NAME="Matsui 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-01 12:53:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsui J, Yahagi N, Kumon K, Hayashi H, Watanabe Y, Haruna M et al</AU>
<TI>Effects of inhaled nitric oxide on postoperative pulmonary circulation in patients with congenital heart disease</TI>
<SO>Artificial Organs</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>1</NO>
<PG>17-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9012900"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2006" MODIFIED="2014-07-01 12:53:26 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-01 12:53:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith HA, Carter JA, Christian KG, Drinkwater DC, Scholl FG, Christman BW et al</AU>
<TI>Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2006</YR>
<VL>132</VL>
<NO>1</NO>
<PG>58-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 16798303"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-01 12:57:47 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-01 12:57:47 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alderson-2002" NAME="Alderson 2002" TYPE="OTHER">
<AU>Alderson P, Green S, editors</AU>
<TI>Cochrane Collaboration open learning material for reviewers (Version 1.1, November 2002)</TI>
<SO>www.cochrane-net.org/openlearning/HTML/modA2-3.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atz-1997" NAME="Atz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Atz AM, Wessel DL</AU>
<TI>Inhaled nitric oxide in the neonate with cardiac disease</TI>
<SO>Seminars in Perinatology</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>5</NO>
<PG>441-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9352616"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bando-1996" NAME="Bando 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bando K, Turrentine MW, Sharp TG, Sekine Y, Aufiero TX, Sun K et al</AU>
<TI>Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>112</VL>
<NO>6</NO>
<PG>1600-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8975852"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beghetti-1995" NAME="Beghetti 1995" TYPE="JOURNAL_ARTICLE">
<AU>Beghetti M, Habre W, Berner M</AU>
<TI>Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients</TI>
<SO>British Heart Journal</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>1</NO>
<PG>65-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7888265"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clark-2000" NAME="Clark 2000" TYPE="JOURNAL_ARTICLE">
<AU>Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA et al</AU>
<TI>Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>7</NO>
<PG>469-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10675427"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CNRG-2004" NAME="CNRG 2004" TYPE="OTHER">
<AU>Cochrane Neonatal Review Group</AU>
<TI>Organization of a systematic review for the Cochrane Neonatal Review Group. Guidelines for reviewers and editors</TI>
<SO>www.cochrane.mcmaster.ca/neonatal/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curran-1995" NAME="Curran 1995" TYPE="JOURNAL_ARTICLE">
<AU>Curran RD, Mavroudis C, Backer CL, Sautel M, Zales VR, Wessel DL</AU>
<TI>Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>60</VL>
<NO>6</NO>
<PG>1765-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8787478"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DiBlasi-2010" MODIFIED="2014-02-19 11:27:44 +0000" MODIFIED_BY="[Empty name]" NAME="DiBlasi 2010" TYPE="JOURNAL_ARTICLE">
<AU>DiBlasi RM, Myers TR, Hess DR</AU>
<TI>Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure</TI>
<SO>Respiratory Care</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>12</NO>
<PG>1717-45</PG>
<IDENTIFIERS MODIFIED="2014-02-19 11:27:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-19 11:27:44 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21122181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2014-02-20 11:37:00 +0000" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finer-2009" MODIFIED="2014-02-05 17:11:44 +0000" MODIFIED_BY="[Empty name]" NAME="Finer 2009" TYPE="COCHRANE_REVIEW">
<AU>Finer N, Barrington KJ</AU>
<TI>Nitric oxide for respiratory failure in infants born at or near term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2014-02-05 17:07:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-05 17:07:34 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gorenflo-2010" MODIFIED="2014-01-20 18:25:19 +0000" MODIFIED_BY="[Empty name]" NAME="Gorenflo 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gorenflo M, Gu H, Xu Z</AU>
<TI>Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease</TI>
<SO>Cardiology</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>1</NO>
<PG>10-7</PG>
<IDENTIFIERS MODIFIED="2014-01-20 18:25:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-20 18:25:19 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20424447"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haworth-1984" NAME="Haworth 1984" TYPE="JOURNAL_ARTICLE">
<AU>Haworth SG</AU>
<TI>Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood</TI>
<SO>British Heart Journal</SO>
<YR>1984</YR>
<VL>52</VL>
<NO>5</NO>
<PG>557-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6498033"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-02-05 17:04:38 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1981" NAME="Jones 1981" TYPE="JOURNAL_ARTICLE">
<AU>Jones OD, Shore DF, Rigby ML, Leijala M, Scallan J, Shinebourne EA et al</AU>
<TI>The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children</TI>
<SO>Circulation</SO>
<YR>1981</YR>
<VL>64</VL>
<NO>2 Part 2</NO>
<PG>II134-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7249314"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Journois-1994" NAME="Journois 1994" TYPE="JOURNAL_ARTICLE">
<AU>Journois D, Pouard P, Mauriat P, Malhere T, Vouhe P, Safran D</AU>
<TI>Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart disease</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>4</NO>
<PG>1129-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8159035"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kinsella-1992" NAME="Kinsella 1992" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Neish SR, Shaffer E, Abman SH</AU>
<TI>Low-dose inhaled nitric oxide in persistent pulmonary hypertension of the newborn</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<NO>8823</NO>
<PG>819-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1357246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" MODIFIED="2014-07-01 12:56:13 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Paper presented at the Fourth International Cochrane Colloquium. 20-24 October, 1996</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1994" NAME="Miller 1994" TYPE="JOURNAL_ARTICLE">
<AU>Miller OI, Celermajer DS, Deanfield JE, Macrae DJ</AU>
<TI>Very low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>108</VL>
<NO>3</NO>
<PG>487-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8078341"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nelin-1998" NAME="Nelin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nelin LD, Hoffman GM</AU>
<TI>The use of inhaled nitric oxide in a wide variety of clinical problems</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1998</YR>
<VL>45</VL>
<NO>3</NO>
<PG>531-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9653435"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NINOS-1997" MODIFIED="2014-07-01 12:56:44 +0100" MODIFIED_BY="[Empty name]" NAME="NINOS 1997" TYPE="JOURNAL_ARTICLE">
<AU>Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>9</NO>
<PG>597-604</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9036320"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.2" MODIFIED="2014-02-05 17:06:47 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 5.2" TYPE="OTHER">
<AU>RevMan 5.2</AU>
<TI>Review Manager (RevMan) [Computer program]</TI>
<SO>Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1992" NAME="Roberts 1992" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD, Polaner DM, Lang P</AU>
<TI>Inhaled nitric oxide in persistent pulmonary hypertension of the newborn</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<NO>8823</NO>
<PG>818-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1357245"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1997" NAME="Roberts 1997" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD, Fineman JR, Morin FC, Shawl PW, Rimar S, Schreiber MD et al</AU>
<TI>Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>9</NO>
<PG>605-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9032045"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Steudel-1999" NAME="Steudel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Steudel W, Hurford WE, Zapol WM</AU>
<TI>Inhaled nitric oxide. Basic biology and clinical applications</TI>
<SO>Anesthesiology</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>4</NO>
<PG>1090-121</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10519513"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wessel-1993" MODIFIED="2014-07-01 12:57:47 +0100" MODIFIED_BY="[Empty name]" NAME="Wessel 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ</AU>
<TI>Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass</TI>
<SO>Circulation</SO>
<YR>1993</YR>
<VL>88 Suppl 1</VL>
<PG>2128-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8222107"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wheller-1979" NAME="Wheller 1979" TYPE="JOURNAL_ARTICLE">
<AU>Wheller J, George BL, Mulder DG, Jarmakani JM</AU>
<TI>Diagnosis and management of postoperative pulmonary hypertensive crisis</TI>
<SO>Circulation</SO>
<YR>1979</YR>
<VL>60</VL>
<NO>7</NO>
<PG>1640-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="498483"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Whittsett-1999" NAME="Whittsett 1999" TYPE="BOOK_SECTION">
<AU>Whittsett JA, Pryhuber GS, Rice WR, Warner BB, Wert SE</AU>
<TI>Acute respiratory disorders</TI>
<SO>Neonatology. Pathophysiology and Management of the Newborn</SO>
<YR>1999</YR>
<PG>499-500</PG>
<EN>5th</EN>
<ED>Avery GB, Fletcher MA, MacDonald MG</ED>
<PB>Lippincott, Williams, &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-01-29 14:41:55 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bizzarro-2005" MODIFIED="2014-01-29 14:41:55 +0000" MODIFIED_BY="[Empty name]" NAME="Bizzarro 2005" TYPE="COCHRANE_REVIEW">
<AU>Bizzarro M, Gross I</AU>
<TI>Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-01-29 14:41:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-29 14:41:20 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005055.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Day-2000">
<CHAR_METHODS MODIFIED="2014-07-01 12:41:42 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 12:41:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>38 participants randomized</LI>
<LI>Included: patients with congenital heart disease who underwent a biventricular repair or heart transplantation with systolic pulmonary arterial pressure 50% higher than systolic systemic arterial pressure</LI>
<LI>Excluded: not reported</LI>
<LI>Age: months (median 6 with range from 1 day to 3 years in control group; 7 with range from 1 day to 20 years in intervention group)</LI>
<LI>Sex distribution: not reported</LI>
<LI>Country: United States of America</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 12:42:03 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>iNO at 20 ppm. Therapy was initiated in the ICU and continued until extubation. Data were collected at 1 hour after initiation of therapy</LI>
<LI>Conventional management as dictated by the attending cardiothoracic surgeon</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 12:42:31 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Number of pulmonary hypertensive crises<BR/>Secondary: Changes in pH, PCO<SUB>2</SUB>, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, heart rate, systemic and pulmonary artery pressures, in addition to the maximum methaemoglobin concentration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>Single centre<BR/>Several patients had radiographic evidence of lung disease before operation in each group<BR/>Could be included in the following subgroup analyses: conventional management</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Miller-2000">
<CHAR_METHODS MODIFIED="2014-07-01 12:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 12:43:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>124 participants randomized</LI>
<LI>Included: infants suitable for corrective heart surgery with high pulmonary flow, pressure, or both, congenital heart lesions, such as non-restrictive ventricular septal defect, complete atrioventricular septal defect, truncus arteriosus, or total anomalous pulmonary venous drainage, with objective evidence of pulmonary hypertension at the immediate preoperative assessment</LI>
<LI>Excluded: not reported</LI>
<LI>Age: months (median 3 with range from 1 to 5 years in treatment group; 2 with range from 1 to 4 in control group)</LI>
<LI>Sex distribution: M/F (36/27, 28/33)</LI>
<LI>Country: Australia</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 12:44:01 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>iNO at 10 ppm</LI>
<LI>Placebo management. Nitrogen was used</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 12:44:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Number of pulmonary hypertensive crises and deaths<BR/>Secondary: Changes in pulmonary and systemic artery pressures as well as pulmonary and systemic vascular resistance indexes, duration of mechanical ventilation, and maximum methaemoglobin level</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>Single centre<BR/>Could be included in the following subgroup analyses: placebo management</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Morris-2000">
<CHAR_METHODS MODIFIED="2014-07-01 12:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 12:44:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>12 participants randomized</LI>
<LI>Included: patients with age 1 month to 17 years, with CHD necessitating repair and with pulmonary hypertension in the postoperative period</LI>
<LI>Excluded: not reported</LI>
<LI>Age: years (authors reported age of each patient)</LI>
<LI>Sex distribution: not reported</LI>
<LI>Country: Canada</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 12:45:05 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>iNO at 5 ppm for 15 minutes followed by 40 ppm for 15 minutes. Therapy was initiated upon arrival in the ICU and continued for 30 minutes</LI>
<LI>Placebo management. Hyperventilation in the control group</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 12:45:10 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Changes in mean pulmonary artery pressure and pulmonary vascular resistance index<BR/>Secondary: Changes in heart rate, cardiac index, stroke index, central venous pressure, left atrial pressure, and mean blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>Single centre<BR/>Could be included in the following subgroup analyses: conventional management</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Russell-1998">
<CHAR_METHODS MODIFIED="2014-07-01 12:45:44 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 12:45:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>35 patients randomized</LI>
<LI>Included: patients with preoperative pulmonary hypertension diagnosed by either cardiac catheterization or echocardiography</LI>
<LI>Excluded: not reported</LI>
<LI>Age: not reported</LI>
<LI>Sex distribution: not reported</LI>
<LI>Country: United States of America</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 12:46:11 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>iNOat 80 ppm. Therapy was initiated in the operating room and continued for 20 minutes</LI>
<LI>Placebo management</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 12:46:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Changes in mean pulmonary artery pressure. Secondary: Changes in heart rate and mean arterial pressure. Median methaemoglobin level was also assessed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-03 13:05:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>Single centre<BR/>Could be included in the following subgroup analyses: placebo management</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Congenital heart disease (CHD)</P>
<P>Female (F)</P>
<P>Inhaled nitric oxide (iNO)</P>
<P>Intensive care unit (ICU)</P>
<P>Male (M)</P>
<P>Nitric oxide (NO)</P>
<P>Number of patients (n)</P>
<P>Parts per million (ppm)<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-07-01 12:47:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-07-01 12:47:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Argenziano-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 12:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>The trial utilized an adult patient population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 12:47:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Checchia-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 12:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>The trial compared inhaled nitric oxide with placebo during cardiopulmonary bypass, not in the postoperative period, and did not assess pulmonary hypertension as an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 12:47:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khazin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 12:47:47 +0100" MODIFIED_BY="[Empty name]">
<P>The trial compared nitric oxide with milrinone and in combination with milrinone, not in placebo or conventional management</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-30 15:52:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirbas-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-30 15:52:49 +0000" MODIFIED_BY="[Empty name]">
<P>The trial compared inhaled nitric oxide with aerosolized iloprost, not in placebo or conventional management</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-30 15:52:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loukhanov-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-30 15:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>The trial compared inhaled nitric oxide with aerosolized iloprost, not in placebo or conventional management</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 12:47:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsui-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 12:47:55 +0100" MODIFIED_BY="[Empty name]">
<P>The study was not a randomized clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 12:47:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 12:47:57 +0100" MODIFIED_BY="[Empty name]">
<P>The trial compared citrulline, a nitric oxide precursor, with placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-01 12:47:22 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-01-16 20:13:28 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-01-16 20:17:35 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-01-16 20:17:35 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-01-16 20:17:35 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-01-16 20:17:35 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-07-01 12:46:26 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Random sequence generation</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>Quote: "Patients were randomized by a blind draw from sequential groups containing six assignments."<BR/>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:44:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>Quote: "Infants were randomised locally by a computer-based stratified minimisation algorithm, based on the presence or absence of Down&#8217;s syndrome ..."<BR/>Comment: Clear. Authors employed a computer-based randomization program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:45:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>Quote: "The design was a crossover study with the order of the treatments randomized."</P>
<P>Comment: Authors did not list specific techniques for randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:46:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to receive nitrogen (placebo) or inhaled NO (diluted in a carrier gas of nitrogen) at an inspired oxygen concentration of 0.90."</P>
<P>Comment: Authors did not list specific techniques for randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-07-01 12:46:30 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:42:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>Quote: "Patients were randomized by a blind draw from sequential groups containing six assignments."</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:44:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>Quote: "On the two types of nitric oxide and nitrogen dioxide monitors, the displays were masked with locked opaque covers."<BR/>Comment: Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:45:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>Comment: Not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:46:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>Comment: Not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-07-01 12:46:32 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of participants and personnel</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 12:42:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>Quote: "Inhaled nitric oxide was then administered to patients in the treatment group in an open labelled, or unblinded manner as previously described ..."<BR/>Comment: Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 12:44:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>Quote: "A non-clinical investigator who was aware of treatment status was available around the clock to supervise randomisation, preparation of the cylinders of study gas, and to set up gas delivery and the monitoring circuit for each patient."<BR/>Comment: Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 12:45:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 12:46:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>Quote: "The operative team (surgeons, anaesthesiologists, and echocardiographers) were blinded to the treatment assigned."<BR/>Comment: Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2014-07-01 12:46:38 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of outcome assessment</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-07-01 12:43:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>Quote: "Inhaled nitric oxide was then administered to patients in the treatment group in an open labelled, or unblinded manner as previously described ..."<BR/>Comment: Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-07-01 12:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>Quote: "The latter radiographs were reviewed independently by a chest physician and radiologist who were unaware of study-gas assignment, and given a predefined lung injury score ..."<BR/>Quote: "When infants were eligible for extubation, the nonclinical investigator reduced the study-gas flow by 20% per h, aiming for complete withdrawal after 4 h."<BR/>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-07-01 12:45:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-07-01 12:46:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>Quote: &#8220;The operative team (surgeons, anaesthesiologists, and echocardiographies) were blinded to the treatment assigned)&#8221;<BR/>Comment: Authors did not comment on this level of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2014-07-01 12:47:15 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Incomplete outcome data</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-07-01 12:43:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>6/44 missing data. 2 were enrolled twice. Two patients were excluded for age &gt; 14 years and 4 were excluded due to cross over. In the final analysis, there were a total of n = 18 treatment and n = 20 controls</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-07-01 12:44:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>No missing data. All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-07-01 12:45:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>Comment: 1 patient was excluded due to age &gt; 14 years. A cross-over design was employed so that 11 patients were subsequently analysed in each group. No missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-07-01 12:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>4/39 missing data</P>
<P>Quote: "Results were obtained in 36 of 40 studies; 4 studies were excluded from the final analysis because of technical difficulties with equipment (n = 1) or surgical decision not to use a pulmonary artery catheter (n = 3). The final data set was thus comprised of 36 studies from 35 patients ... "<BR/>Comment: Which group these patients were initially assigned to was not described. One patient was analysed twice (at different times)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-07-01 12:47:19 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Selective reporting</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:43:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:44:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:45:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>Comment: All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:47:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>Comment: All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-07-01 12:47:22 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Other bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-2000">
<DESCRIPTION>
<P>Quote: "We may have failed to identify all patients with a systolic pulmonary arterial pressure of 50% or more of the systolic systemic pressure, and some patients with an initially low pulmonary arterial pressure may have developed a subsequent increase in pressure that was not monitored."<BR/>Comment: Eligible patients could not be included in this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:44:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 12:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Russell-1998">
<DESCRIPTION>
<P>Quote: "Methemoglobin levels were measured in 9 patients who received inhaled NO and 11 patients who did not."<BR/>Comment: Methemoglobin analysis was compromised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-07-01 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-07-01 12:49:40 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-02-19 15:42:12 +0000" MODIFIED_BY="Grade Profiler">Inhaled nitric oxide compared to placebo or conventional therapy for all infants and children with congenital heart disease having postoperative management of pulmonary hypertension</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Inhaled nitric oxide compared to placebo or conventional therapy for all infants and children with congenital heart disease having postoperative management of pulmonary hypertension </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> all infants and children with congenital heart disease having postoperative management of pulmonary hypertension<BR/>
<B>Settings:</B> postoperative<BR/>
<B>Intervention:</B> inhaled nitric oxide<BR/>
<B>Comparison: </B>placebo or conventional therapy</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or conventional therapy</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Inhaled nitric oxide</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Long-term mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>No studies met outcome definition</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality prior to discharge</B>
<SUP>1</SUP>
<BR/>Follow-up: mean 15 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.67 </B>
<BR/>(0.38 to 7.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>162<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>37 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
<BR/>(14 to 219)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(10 to 158)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Difference in MPAP change score (SE) - Conventional Management</B>
<SUP>4</SUP>
<BR/>Follow-up: mean 5 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-1.14 (-8.87 to 6.59)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Difference in MPAP change score (SE) - Placebo</B>
<SUP>4</SUP>
<BR/>Follow-up: mean 5 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-9.15 (-20.7 to 2.4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Difference in MAP change score (SE) - Conventional Mangement</B>
<SUP>4</SUP>
<BR/>Follow-up: mean 5 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,5,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-1.94 (-11.23 to 7.35)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Difference in MAP change score (SE) - Placebo</B>
<SUP>4</SUP>
<BR/>Follow-up: mean 5 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-10 (-28.6 to 8.6)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> One of the two trials had zero events (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>).<BR/>
<SUP>2</SUP> Statistical heterogeneity could not be measured. One of the two trials had zero events (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>).<BR/>
<SUP>3</SUP> There was very low precision because of the small numbers and the low rate of events (only 162 patients and 8 events). One of the two trials had zero events (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>).<BR/>
<SUP>4</SUP> Pre-specified subgroup analysis.<BR/>
<SUP>5</SUP> One of the two trials included was assessed as having a low risk of bias (<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>).<BR/>
<SUP>6</SUP> Pre-specified subgroup analysis. Study was assessed as having high risk of bias (<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>).<BR/>
<SUP>7</SUP> Statistical heterogeneity could not be measured.<BR/>
<SUP>8</SUP> There was very low precision because of the small numbers (only 50 patients).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE>Individual number of entries for outcome, "Difference in MPAP change score (SE)"</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>iNO (N)</P>
</TH>
<TH>
<P>Control (N)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>
</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>
</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>
</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Number of entries (N)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE>Individual number of entries for outcome,"Difference in MAP change score (SE)"</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>iNO (N)</P>
</TH>
<TH>
<P>Control (N)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>
</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>
</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>
</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Number of entries (N)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2014-07-01 17:50:07 +0100" MODIFIED_BY="Jane Cracknell" NO="3">
<TITLE MODIFIED="2014-07-01 12:50:15 +0100" MODIFIED_BY="[Empty name]">Individual number of entries for outcome, 'Difference in HR change score (SE)'</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>iNO (N)</P>
</TH>
<TH>
<P>Control (N)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Russell-1998" TYPE="STUDY">Russell 1998</LINK>
</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Day-2000" TYPE="STUDY">Day 2000</LINK>
</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morris-2000" TYPE="STUDY">Morris 2000</LINK>
</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Number of entries (N)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-02-03 15:12:54 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-02-03 15:12:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Inhaled nitric oxide versus placebo or conventional management</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.298935458118276" CI_START="0.38057300187360626" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.863259523356329" LOG_CI_START="-0.4195620241236163" LOG_EFFECT_SIZE="0.2218487496163564" METHOD="MH" MODIFIED="2008-01-15 15:17:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.49783194522970864" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="81" WEIGHT="100.0" Z="0.6779049823687192">
<NAME>Mortality prior to discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-15 15:17:22 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.0" STUDY_ID="STD-Day-2000" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.298935458118278" CI_START="0.3805730018736062" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8632595233563292" LOG_CI_START="-0.4195620241236164" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2008-01-15 15:15:14 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.7535357270587926" STUDY_ID="STD-Miller-2000" TOTAL_1="63" TOTAL_2="61" VAR="0.567816091954023" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.183952875694258" CI_START="0.15296539397418585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="100.00000000000001" ID="CMP-001.02" LOG_CI_END="0.6215867843818753" LOG_CI_START="-0.8154068103979881" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" MODIFIED="2008-01-08 14:30:26 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.7915043306080578" Q="1.0812238284279217E-33" RANDOM="NO" SCALE="694.9133296610737" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0" Z="0.2643576644003011">
<NAME>Pulmonary hypertensive crises</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.183952875694257" CI_START="0.15296539397418588" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6215867843818752" LOG_CI_START="-0.815406810397988" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="3" O_E="0.0" SE="0.8440971508067066" STUDY_ID="STD-Day-2000" TOTAL_1="18" TOTAL_2="20" VAR="0.7124999999999999" WEIGHT="100.0"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="3.6197019149636054" CI_END="3.403243516980622" CI_START="-9.278562495501195" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="-2.937659489260286" ESTIMABLE="YES" I2="44.74683145227694" I2_Q="21.577416804577386" ID="CMP-001.03" LOG_CI_END="0.5318930258801516" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-02-03 15:12:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16367859743166369" P_Q="0.2588041918746625" P_Z="0.3638643283421529" Q="1.2751428979431632" RANDOM="YES" SCALE="68.57" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="14.258753328307252" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="100.00000000000001" Z="0.908026316145442">
<NAME>Difference in MPAP change score (SE)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Change in MPAP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.3845356810741305" CI_END="6.592002801796964" CI_START="-8.874966022770746" DF="1" EFFECT_SIZE="-1.1414816104868915" ESTIMABLE="YES" I2="58.06311442781418" ID="CMP-001.03.01" LOG_CI_END="0.8190173832771513" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-01-10 22:16:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1225414773151805" P_Z="0.7723551960786385" STUDIES="2" TAU2="18.626676139999997" TOTAL_1="2" TOTAL_2="2" WEIGHT="78.634069218442" Z="0.28929557833147257">
<NAME>Conventional Management</NAME>
<IV_DATA CI_END="1.067882421996769" CI_START="-9.987882421996769" EFFECT_SIZE="-4.46" ESTIMABLE="YES" ESTIMATE="-4.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="2.8204" STUDY_ID="STD-Day-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="47.118430461952784"/>
<IV_DATA CI_END="12.082507210296672" CI_START="-4.982507210296672" EFFECT_SIZE="3.55" ESTIMABLE="YES" ESTIMATE="3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="4.3534" STUDY_ID="STD-Morris-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="31.515638756489203"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.4002637572929935" CI_START="-20.700263757292994" DF="0" EFFECT_SIZE="-9.15" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.38025896756285743" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-01-10 22:16:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12050359820543603" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="21.365930781558017" Z="1.5526632841798036">
<NAME>Placebo</NAME>
<IV_DATA CI_END="2.4002637572929935" CI_START="-20.700263757292994" EFFECT_SIZE="-9.15" ESTIMABLE="YES" ESTIMATE="-9.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="528" SE="5.8931" STUDY_ID="STD-Russell-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="21.365930781558017"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.6858368515130913" CI_END="4.761249217470076" CI_START="-11.85625350031291" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="-3.5475021414214174" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.6777209142910124" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-01-10 22:24:49 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7096961841396232" P_Q="0.4473594905806709" P_Z="0.4026905735930506" Q="0.577333613807831" RANDOM="NO" SCALE="58.432030295853515" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="99.99999999999999" Z="0.836825671143001">
<NAME>Difference in MAP change score (SE)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Change in MAP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.10850323770526037" CI_END="7.346944373133735" CI_START="-11.226035486939422" DF="1" EFFECT_SIZE="-1.9395455569028435" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.8661067516270741" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-01-10 22:24:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.741854692122938" P_Z="0.6822816600341848" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="80.0512912036169" Z="0.40935159210249444">
<NAME>Conventional Mangement</NAME>
<IV_DATA CI_END="10.229864398280766" CI_START="-17.589864398280767" EFFECT_SIZE="-3.68" ESTIMABLE="YES" ESTIMATE="-3.68" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="7.097" STUDY_ID="STD-Day-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="35.6800729071203"/>
<IV_DATA CI_END="11.933406794011358" CI_START="-13.01340679401136" EFFECT_SIZE="-0.54" ESTIMABLE="YES" ESTIMATE="-0.54" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="6.3641" STUDY_ID="STD-Morris-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="44.37121829649661"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="8.602802162863473" CI_START="-28.602802162863473" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.9346399356213153" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-01-10 22:24:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.292072814345523" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.948708796383087" Z="1.0535853509492803">
<NAME>Placebo</NAME>
<IV_DATA CI_END="8.602802162863473" CI_START="-28.602802162863473" EFFECT_SIZE="-10.0" ESTIMABLE="YES" ESTIMATE="-10.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="530" SE="9.4914" STUDY_ID="STD-Russell-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.948708796383087"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.1174397220773125" CI_END="8.177891774630528" CI_START="-8.129692360342723" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.02409970714390168" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.9126413588483282" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.6179882348757648" MODIFIED="2008-01-10 22:29:36 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5719409026218685" P_Q="0.7354311563009162" P_Z="0.9953779157599276" Q="0.11418307972314147" RANDOM="NO" SCALE="67.42741860899464" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="100.00000000000001" Z="0.005792955921497985">
<NAME>Difference in HR change score (SE)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Change in HR</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.0032566423541711" CI_END="8.099892305806687" CI_START="-8.84599032840201" DF="1" EFFECT_SIZE="-0.3730490112976618" ESTIMABLE="YES" I2="0.3246071061667039" ID="CMP-001.05.01" LOG_CI_END="0.9084792446434874" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-01-10 22:29:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31652403625738645" P_Z="0.9312328366590324" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="92.6085037079227" Z="0.08629383814280563">
<NAME>Conventional Management</NAME>
<IV_DATA CI_END="7.70715455464047" CI_START="-19.007154554640472" EFFECT_SIZE="-5.65" ESTIMABLE="YES" ESTIMATE="-5.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="531" SE="6.815" STUDY_ID="STD-Day-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="37.264162235242416"/>
<IV_DATA CI_END="14.140314597946437" CI_START="-7.780314597946438" EFFECT_SIZE="3.18" ESTIMABLE="YES" ESTIMATE="3.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="532" SE="5.5921" STUDY_ID="STD-Morris-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="55.34434147268027"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="34.99117289503346" CI_START="-24.991172895033458" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.5439585001652045" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-01-10 22:29:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7438518304600463" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="7.391496292077316" Z="0.32675680797809425">
<NAME>Placebo</NAME>
<IV_DATA CI_END="34.99117289503346" CI_START="-24.991172895033458" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="15.3019" STUDY_ID="STD-Russell-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="7.391496292077316"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="62.56884785355116" CI_START="-28.208847853551163" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="17.18" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2008-01-08 14:30:57 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.4581720276992344" Q="0.0" RANDOM="NO" SCALE="209.32075170635613" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.7418602332238682">
<NAME>Difference in PaO2:FiO2 change score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="62.56884785355116" CI_START="-28.208847853551163" EFFECT_SIZE="17.18" ESTIMABLE="YES" MEAN_1="39.04" MEAN_2="21.86" ORDER="13" SD_1="53.42" SD_2="86.92" SE="23.158000969187494" STUDY_ID="STD-Day-2000" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.36367788626848063" CI_START="0.236322113731519" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-01-08 14:31:04 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="2.6118464948151233E-20" Q="0.0" RANDOM="NO" SCALE="1.162082664822922" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="9.23380516876638">
<NAME>Maximum methaemoglobin level</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.36367788626848063" CI_START="0.236322113731519" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.1" ORDER="14" SD_1="0.1" SD_2="0.1" SE="0.03248931448269655" STUDY_ID="STD-Day-2000" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-07-01 12:47:23 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-02-03 19:56:01 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArIAAAKCCAYAAAAtAzotAABwkElEQVR42uydD2SV7///PyRJkkje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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-01 12:47:23 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATUAAAFhCAIAAACeYqqyAAAQzklEQVR42u3dsW4UyRbG8ZGQEIED
B34CnsERsogg4p0gdIAEod8C8Qgr2A1ZIjLEYq8WBwQ2ZLsL6tte32A07pnpGXf1nNP1+zS6sgz3
26Gq/n3Oqaqums2IKLIaIoonfBLhk4jwSYRPIsInET7xSYRPIsInET6JCJ80RAfbNIZPIsInET5p
oonu9c8aBJ8UqJuX/UD4JHwSPgmf+KTU9acexycR4ZMInzS9/Fan45MCdbNGwCfhk/BJEMUnTbj4
1On4JCJ8EuGTJpbiahN8UpRu1gj4JHwSPgmi+KQJF586HZ9EhE8ifNKUUlwNgk8K1M1rfxPNmfCJ
z8ECsuCMT0oQPwmfpP7EJ9FWia42wScFzZwJn7Q9SMP2uMGDTxoSzsG5Mn7wSUH5tL6CTwodPwmf
NExPgxOfVOUYcvMvPumW+a3MGZ9UEaL4xCcNloIOPsuKT3wmGO5aQ1Pgc+K1HBE+K+XTLCs+IRr9
Cxfa3yfFxWfc4jN+Axbd32dI4JPwiU+qJuwryPFprFea8Bsh+Nx9riiACJ74xGfomG/w4BOfob+z
8YNP9WdQPp2fgE8aGFE9jk+KG/DFOnxONgQZ5csis6bAJ8WFU/KMz1iFnBGJT3yq4vCJT9o2fmoQ
cOKTxHx80laDPlfY1+P4rKXiqnz/UGN9BZ+R+Wzq3n9rfgif+Bw+J6+8NfBZC6I2D+ETnxR9DIET
n0FruUw9bX0FnxD1hQmfUQJRxvnbEg3iQYBPioWok+nxSXFj/ggnX9ccmfEpo8vBZ51NjU/jZuDg
rJ3xic8qajn7QPBZBZ9qOXzK6Cp9phSKcs6RwaeYH9HZO+X4rBrRFLM4hiU+B3vAw95sNj5jjUi6
GZAHv/lXfovPKHyaEVkRma2v0M4QNSMic8ZnQZZqzpzTzTzhk1AU9zvjkwYLzsEpEuXwGZeiJslF
8fjEp3mLGvlsCqyvmC3DZ/SKq1BP5wpx7qTAZ6z4KWKsAFL8pG1Aqnysj7bahE+a+KOk9Mxw0f19
8luKglNT/cww4XPIiFTnWMcnPkOXc8O+l1xurJebebLLB59B4Ry29PKuM+EzLp9N+bMqCZ/VlaAp
GMjYy84Bx2eND5Rcdzp5vwyfcUFSR+ATn1LQcFkoPvFZEZ/p3ixt7B/CZyWIltuFJ8rhs5aMrnF+
AuEz/lhP9J2LZqFmy/BZBZ9Nwl14hiU+I8YiLawp8Bkxo0t6fsIIO+/xSZ4pEXPyQrNlWR6F+Kw0
V0w0p1XaPPLMMz4H690ST/QUZ/mUXrMd7WmFT7FoOs+UvPUnPvEZuvgckKXSB/aOMxUnvzXXsuNY
lLFKJHxGHOu53kg2fvBZI5/NcGcaFZ15GjkLrSpPwWeg3rXXfJw6P1Gr4jNW7zqrEp/4rLHcGm19
JT6fuWp7fE4f0TFjUfz6M9E+Z3wGnREpHS7cMiZ+0vbFZ6JYhE984jNNQhG5Zi692oTPWCOycdZW
wppZ/BTlosSidBFDzYxPUa4USMFXbkq/x4dPfIpFw39n+e00688UMyJJ3/y2fwif9Ua5yrNQ+4dI
xAj6ndWfFSW3id6oyvVMIXzWEpoKnWxSurJ1vwM+K80e0/3bU7xzg8+Jj1ERY4R2tj+hrvozRSya
QBaKT5pmrjjayWMpUgl8UixEx9zzVPk7N/gMl98WnRHFp8GmQbcfgulOqS19VkiFUQ6foVNQDZiu
neW3xo2IEbSdzQ/VVYJWTn661sAn1TIi8z5TUpQn+MRnddV4olMU8HmrDm7y7AstFDHMluEzaJTL
db5JuYhhTguf+KQcGRA+p8xnxp0PehCfodNFtVyuKIdPisJn3n225SjCJ0WJzOVKrNFeVUt0WxQ+
wxUweSdvIzs35uHwWc+4SZrlJj2nYsBnNz4915X6cccGPmvh0/741Wk5PqdWFeSCs9xYH9w53S1j
+KxsPsAtRmmrhmGf3ficflHUeH8l+/NaQ0ybz4z1Z5Nnlyw+IVpvU6Seh1N/Trn4dLNLU3j/UFNy
Z6/6cwrPSBqZz0TOhpcUNM1zsELy8RmLT2F5ApnzfFfKb6eD6Mg7ZuJvkfccxGeg+rP0WZUrAkgo
57z7h/A55fx2/F0EJd7/znKoT4m+G/yZgs8q6k98rmhq8ROiQSuucudrJjq5MzIC+BymOtIsibL9
ovGzyJWwRkOEsYj80arxLDPw+Kw37KdwzlVT4DNuLRc8YqQrxUussoyQpwz7TMFnCIpKr/jlPQU3
9ayE9ZWp1UVjfu1qEXU/Lz4TPN2DO5eobNPtTMJnoPqz8eaagI/P+COy5hM9VLb4zMFnM9z+uxIZ
3chzoeXgj/yF8RmoenEy/TjZ/mjvCeFz96nX4P0x3zEaeRznsLNl+Iz19E0U8/Ou2Tbez8ZnhTG/
qHPVGT7qgjx9R5u3SHG/Q8bVpmFP7sRnFZHZ/Q5FKeqcPhikNfBZS+ac8X6H0u3sfM0q8tsUFKkj
8FlplKOk2X7RmyOcn4DPiDE/yy4C6ysQDZfR5WoKmQs+BwgXNd9FbRdB0WwCn1VUXI3XtZY/WyPv
ecJnLTMiGd/PVvjgM9CMSGN9ZflwT5Tf4jNEB3iLOnW2P+z+IeeDBeWzCf/+SpPz/eyk65/y2wny
6Ua9MbP9EfYPDfVMMQhu28FazxNWfkvhInPqmJ9lHwg+J07RxJql0hZAyKYjpuhTk5oJXbKKzx2M
mPnZy6KdPewzpdDmhKbAdZrlrgBcmD6IPOGMz+35LDqASgyawa/WKuRctJwboTUG/Cfgc4DeLRGL
co3IEi1Tbs0Wn/i8Ve/ic+QexCc+xc8p86n+DNG7I6yCjPB+SfD1z6LtvGAV/PUGfEZ/HGgHY8Ag
IMInEeGTCJ9EhE8ifFKzcmafqJzw2ZdPzpzjOOPTuOGMT3xy5oxPvcsZn/jkzBmf+OSMT3z274OL
fy+OT4+P3h/t/7o/+2W293bv8N3hsz+eff3na1jnfy8uTo+P3x8d/bq//8ts9nZv793h4R/Pnv3z
Na5zxnb++fPi8vL4/Pzo7Gz/8+fZ6enely+HFxfPfv78is8x+Dz56+Tgt4O2U29+2s5++efLgM5/
nZz8dnDQZTxrofrzZUTnjO38/fvJ2dlBi+XNT4vrt28v8VmWz/YR29mv85/274RybkPZOuNZ+3dC
OWds5zZIdpI5/2n/Dj5L8dk+d9d27fVn2TN4fOc2vvUzni2LdeM7Z2znNnKuhfP6syyK7p7P4U+8
v3Fgz21+ubql2oplWVLUmSad/32+c+e2MlyWfHamo3+f7945Yzu3Ned8Wvvmzezhw9m9e1efJ09m
v/++mOj++HEelM9BpsI6z4y55S/XfrHj0+OeXbsiRxrZ+fT4eBPj7lx0ZOeM7Xx5eTxP4P37VzS9
fj179erqhwcPemW54fhsus6S7U/RyHwevT/q6MVrdfXu4bvDnTu/PzraiKJ3h7t3ztjO5+dHnans
x49X3nfvLv7+y5fDZHx2Hsoeis/rifj+vbv3dm/nztcLHv0/b/d275yxna+XUhY+Hz7MHj268n7x
YvGPTk/38sXPZSD1gXMEPrv7dV43OnjnzjdH3cEa4907Z2znzuD5+PGV5dOn3bNEifPbmHyKn+Ln
RvHzzp0r40+fOuDMFz9XgNRzllX9qf6MVn8u++SoP5fB06fyXBuKzd+av93V/O3151r9dylEX//s
vNdgGT+dPtY/rX9GWP9czWfc9c9BUuId/kftHxrH2f6hHHzu6ivZf7tzZ/tvc8TPgM+F9hncPRP4
X1L0/Ox5QOc21i2bcW1/f/Y8onPGdv7v/ZX95e+vbOmMz83i9rK3BzsrliDOy97S7KwMgzhnbOdl
73921pz4jJVXc+aMT73LGZ/45MwZn/jkjE98Gjec8YlPzpzxecuWInJ/mfjJmbP4adxwxic+OXPG
Jz454xOfnDnjE5+cOeNzyD7IeK8W57zO+NygDzLeq8U5tTM++7ZUxvf6OWd3xmevlsp4Lg7n7M7D
89nnnNvO0y43+k+4v4zz5J1L8Xnz2Mu1xG7Hv/vLOE/YeWw+V8fPziNtG/eXca7VuWB+e/N/+ye6
y46T3yGfGe8F4ZzdOQGfmya6jfvLOE/FORafy64wi8Cn5zpn8XOzLz3gpJG6iHNd9efWP/TJb91f
xtn87ah8rpi/Xbb46f4yztY/q5N9LZynvH9oqnw29oVytv82Mp9Nznu1OKd2xucGfdDkvFeLc15n
fG7WB5w5j+mMT+OGMz7xyZkzPvUuZ3zikzNnfOKTMz7xudgcRO4vEz85cxY/jRvO+MQnZ874xCdn
fOKTM2d84pMzZ3wO1Qc/f15cXh6fnx+dne1//jw7Pd378uXw4uLZz59fwzr/e3Fxenz8/ujo1/39
X2azt3t77w4P/3j27J+vcZ3dX4bPjfvg+/eTs7ODFp6bnxaqb99eBnT+6+Tkt4ODzneGW6j+fBnR
2f1l+Ny4pdpQ1snP/Kf9O6Gc21C29tiN9u+EcnZ+Aj435rONb2sRuv4si3XjO7fxreexcsti3fjO
zh8amM/Vp12WKL7Hv7+srQznk883b2YPH87u3bv6PHky+/33xXT0x4/znTu3leGy5LMzHf37fPfO
zu8rwufaC8sKxbfR7l+5vDye5+T+/at/4+vXs1evrn548KBXLjqy8+nx8SbHsnbnoiM7O/92bD5X
30rWecz82hA3Pp/n50edCefHj1df8u7dxd9/+XK4c+f3R0cbUfTucPfOzo8vld+uvtChWXIr2erb
B5veV7CU5vN6wWPh8+HD7NGjq+//4sXiH52e7u3c+XrBo//n7d7und2/EoLP/snqpoluIT47Q9zj
x1ft9vRp91zOzp1vjo2DNddq7d7Z/WUJ+OyZ347JZ2eUu3Pn6ht++tSB0C3j5yDO4qf4WYrPtd97
5PvLllWJyz63rz9v76z+VH92D/0B89ueCI08f3v9uVb/vQQjO5u/NX/bC8sVt5Jtkd/u5P6yhVXK
1RTdZv1zQGfrn9Y/Jyj7h3brbP8QPrfhs7H/dixn+2/xuQ2fzf/fMtlf/pbJ84DObaxbNuPa/v7s
eURn95fhc5s+aJa/pdlZGQZxXvaWZmdlGMTZ/WX43KYPOHMe0xmfxg1nfOKTM2d86l3O+MQnZ874
xCdnfOJzsTmI3F8mfnLmLH4aN5zxiU/OnPGJT874xCdnzvjEJ2fO+ByqDzLeX1buxi6tMa8St7nh
c4M+yHh/Wbkbu7TGvArd5obPvi2V8fyEcu/1a415lTtNAp+9Wirj+UPlzsXRGguRs9BpTH357L8d
aVhI+p+y5/6ym1VWoXPltMZCzVnoNMPN+BxtLmstn53Irf7/Vnh/WblzWbXGvMqdBjwMnxudYdvz
lyv4vHnZWeP+snHPNdca8yp3mn5BPof6ZZD7HTLeX1buXhCtMa9yt9EMU3/2v4Ns7S9vz+eyCwv7
X740mfvLyt2rpTXmVe42ty3jZ5/YtVEqexP7reeHOr9DU+X9ZSPHz2pbI0r87MnkpmFziz9d++/p
aTjt+8vGrz/rbI2I9Wefi7GnVH9mvL9stPnbylsj+vzt6txy8PnbCOufKe4vG239s/LWCLH+WY/s
mNEa+fYP4bOx41Rr2H8bmc8m5/1l5W7s0hoLUbTEbW743KAPmpz3l5W7sUtrLNSig9/mhs/N+oAz
5zGd8WnccMYnPjlzxqfe5YxPfHLmjE98csYnPhebg8j9ZUTUK2BoCCJ8EhE+ifBJRPgkwicR4ZOI
NuOTiGLqf7HhPtbdZmTMAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-01 12:47:23 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfIAAAEACAMAAAB/FQTwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-07-01 12:47:23 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Inhaled nitric oxide versus placebo or conventional management, outcome: 1.1 Mortality prior to discharge.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu8AAACgCAMAAACLzHLzAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-07-01 12:59:20 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-07-01 12:58:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-07-01 12:58:34 +0100" MODIFIED_BY="[Empty name]">Search strategy for CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-08 14:19:33 +0000" MODIFIED_BY="Karen Hovhannisyan">
<TABLE COLS="1" ROWS="1">
<TR>
<TD>
<P>#1 HEART DEFECTS CONGENITAL</P>
<P>#2 (congenital near heart)</P>
<P>#3 (heart near defect*)</P>
<P>#4 (heart near abnormal*)</P>
<P>#5 (#1 or #2 or #3 or #4)</P>
<P>#6 NITRIC OXIDE</P>
<P>#7 (nitric next oxide)</P>
<P>#8 ino</P>
<P>#9 (#6 or #7 or #8)</P>
<P>#10 (#5 and #9)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-07-01 12:58:53 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-07-01 12:58:53 +0100" MODIFIED_BY="[Empty name]">Search strategy for MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-08 14:24:12 +0000" MODIFIED_BY="Karen Hovhannisyan">
<TABLE COLS="1" ROWS="11">
<TR>
<TD>
<P>#1 exp Heart Defects, Congenital/</P>
</TD>
</TR>
<TR>
<TD>
<P>#2 (congenital$ adj3 heart).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#3 (heart adj3 defect$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#4 (heart adj3 abnormal$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#5 or/1-4</P>
</TD>
</TR>
<TR>
<TD>
<P>#6 Nitric oxide/</P>
</TD>
</TR>
<TR>
<TD>
<P>#7 nitric oxide.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#8 ino.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#9 or/6-8</P>
</TD>
</TR>
<TR>
<TD>
<P>#10 5 and 9</P>
</TD>
</TR>
<TR>
<TD>
<P>+ RCT filter terms.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-01 12:59:01 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-07-01 12:59:01 +0100" MODIFIED_BY="[Empty name]">Search strategy for EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-15 19:02:59 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="32">
<TR>
<TD>
<P>#1 exp CHD/</P>
</TD>
</TR>
<TR>
<TD>
<P>#2 (congenital$ adj3 heart).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#3 (heart adj3 defect$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#4 (heart adj3 abnormal$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#5 or/1-4</P>
</TD>
</TR>
<TR>
<TD>
<P>#6 Nitric oxide/</P>
</TD>
</TR>
<TR>
<TD>
<P>#7 nitric oxide.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#8 ino.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>#9 or/6-8</P>
</TD>
</TR>
<TR>
<TD>
<P>#10 5 and 9</P>
</TD>
</TR>
<TR>
<TD>
<P>#11 random$.ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#12 factorial$.ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#13 (crossover$ or cross over$ or cross-over$).ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#14 placebo$.ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#15 (double$ adj blind$).ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#16 (singl$ adj blind$).ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#17 assign$.ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#18 allocat$.ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#19 volunteer$.ti,ab.</P>
</TD>
</TR>
<TR>
<TD>
<P>#20 Crossover Procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>#21 Double Blind Procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>#22 Randomized Controlled Trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>#23 Single Blind Procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>#24 or/11-23</P>
</TD>
</TR>
<TR>
<TD>
<P>#25 exp animal/</P>
</TD>
</TR>
<TR>
<TD>
<P>#26 nonhuman/</P>
</TD>
</TR>
<TR>
<TD>
<P>#27 exp animal experiment/</P>
</TD>
</TR>
<TR>
<TD>
<P>#28 or/25-27</P>
</TD>
</TR>
<TR>
<TD>
<P>#29 exp human/</P>
</TD>
</TR>
<TR>
<TD>
<P>#30 28 not 29</P>
</TD>
</TR>
<TR>
<TD>
<P>#31 24 not 30</P>
</TD>
</TR>
<TR>
<TD>
<P>#32 10 and 31</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-07-01 12:59:20 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-07-01 12:59:20 +0100" MODIFIED_BY="[Empty name]">Data extraction form</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-20 11:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>DATA EXTRACTION FORM</P>
<P>REVIEW ID</P>
<TABLE COLS="1" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>Study Id:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Authors:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Medline Journal Id:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Year of Publication:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Language:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type of study:</P>
<P>RCT ( )</P>
<P>CCT ( )</P>
<P>Non-randomized ( )</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Comments on Study Design:</P>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<P/>
<P>Quality of Concealment of Allocation</P>
<P/>
<TABLE COLS="2" ROWS="28">
<TR>
<TD VALIGN="TOP">
<P>Quality of Concealment of Allocation</P>
</TD>
<TD VALIGN="TOP">
<P>Points</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Allocation was not concealed (e.g. quasi-randomization)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Allocation concealment was not stated or was unclear</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Disclosure of allocation was a possibility</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Allocation was concealed (e.g. numbered, sealed opaque envelopes drawn NON consecutively)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Inclusion and exclusion criteria were not clearly defined in the text</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Inclusion and exclusion criteria were clearly defined in the text</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcomes of patients who withdrew or were excluded after allocation were NEITHER detailed separately NOR included in an intention to treat</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcomes of patients who withdrew or were excluded after allocation were EITHER detailed separately OR included in an intention to treat analysis OR the text stated there were no withdrawals</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment and control groups were NOT adequately described at entry</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment and control groups were adequately described at entry</P>
<P>A minimum of 7 admission details were described</P>
<P>(e.g. age, sex, mobility, type of surgery, ASA grade, function score, mental test score</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The text stated that the care programmes other than trial options were NOT identical</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The text stated that the care programmes other than trial options were identical</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome measures were NOT clearly defined in the text</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome measures were clearly defined in the text</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome assessors were NOT blind to the allocation of patients</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome assessors were blind to the allocation of patients</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The timing of the measurement of the outcomes was NOT appropriate</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The timing of the measurement of the outcomes was appropriate</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total number of points</P>
</TD>
<TD VALIGN="TOP">
<P>/10</P>
</TD>
</TR>
</TABLE>
<P/>
<P>METHODS</P>
<TABLE COLS="4" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>Subject-Blinded</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Yes ( )</P>
</TD>
<TD VALIGN="TOP">
<P>No ( )</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear ( )</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Physician-Blinded</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Yes ( )</P>
</TD>
<TD VALIGN="TOP">
<P>No ( )</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear ( )</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome Assessor-Blinded</P>
</TD>
<TD VALIGN="TOP">
<P>Yes ( )</P>
</TD>
<TD VALIGN="TOP">
<P>No ( )</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear ( )</P>
</TD>
</TR>
</TABLE>
<P/>
<P>PARTICIPANTS</P>
<TABLE COLS="2" ROWS="2">
<TR>
<TD VALIGN="TOP">
<P>Number of eligible participants: ___</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Number enrolled in study: ___</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number of males: ___</P>
<P>Number age 0 yo 3 months: ___</P>
<P>Number greater than 6 months to 12 months: ___</P>
</TD>
<TD VALIGN="TOP">
<P>Number of females: ___</P>
<P>Number age 3 to 6 months: ___</P>
<P>Number greater than 12 months: ___</P>
</TD>
</TR>
</TABLE>
<P/>
<P>INTERVENTION</P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>INTERVENTION</P>
</TD>
<TD VALIGN="TOP">
<P>Drugs(specify)/Therapy</P>
</TD>
<TD VALIGN="TOP">
<P>Dose</P>
</TD>
<TD VALIGN="TOP">
<P>Duration</P>
</TD>
<TD VALIGN="TOP">
<P>Rule</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group 1:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group 2:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<P/>
<P>COMMENT ON TREATMENT</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P/>
<P> </P>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="4" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>Withdraws: ___</P>
</TD>
<TD VALIGN="TOP">
<P>Yes ( )</P>
</TD>
<TD VALIGN="TOP">
<P>No ( )</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear ( )</P>
</TD>
</TR>
</TABLE>
<P/>
<P>OUTCOMES</P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>OUTCOMES</P>
</TD>
<TD VALIGN="TOP">
<P>Day in hospital (mean)</P>
</TD>
<TD VALIGN="TOP">
<P>Death in hospital (n,%)</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term death (n,%)</P>
</TD>
<TD VALIGN="TOP">
<P>Neurologic morbidity (specify)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group 1:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group 2:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="5" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>OUTCOMES</P>
</TD>
<TD VALIGN="TOP">
<P>Change in mean airway pressure</P>
</TD>
<TD VALIGN="TOP">
<P>Change in mean systemic pressure</P>
</TD>
<TD VALIGN="TOP">
<P>Change in heart rate</P>
</TD>
<TD VALIGN="TOP">
<P>Maximum methaemoglobin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group 1:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group 2:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>CHANGES IN PROTOCOL:</P>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>CONTACT WITH AUTHOR:</P>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>OTHER COMMENTS ON THIS STUDY:</P>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Total included trials 4&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Hand search reference 0&lt;/p&gt;&lt;p&gt;Articles identified 0&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 full articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Wrong population 1&lt;/p&gt;&lt;p&gt;Wrong study 1&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Total excluded 2&lt;/p&gt;&lt;p&gt;Included trials 4&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Initial search (from inception to January 2004)&lt;/p&gt;&lt;p&gt;79 records identified (CENTRAL, MEDLINE, EMBASE)&lt;/p&gt;&lt;p&gt;6 articles identified&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 full articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Wrong control 2&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Total excluded 2&lt;/p&gt;&lt;p&gt;Included trials 0&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Updated search (from January 2004 to November 2007)&lt;/p&gt;&lt;p&gt;33 records identified (CENTRAL, MEDLINE, EMBASE)&lt;/p&gt;&lt;p&gt;2 article identified&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Wrong control 2&lt;/p&gt;&lt;p&gt;Wrong outcome 1&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Total excluded 3&lt;/p&gt;&lt;p&gt;Included trials 0&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Updated search (from November 2007 to December 1, 2013)&lt;/p&gt;&lt;p&gt;52 records identified&lt;/p&gt;&lt;p&gt;(CENTRAL, MEDLINE, EMBASE)&lt;/p&gt;&lt;p&gt;3 articles identified&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>